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1.0 Introduction 
Natural killer (NK) cells are white blood lymphocytes of the innate immune system that have 
diverse biological functions, including recognition and destruction of certain microbial 
infections and neoplasms [1]. NK cells comprise ~ 10% of all circulating lymphocytes and are 
also found in peripheral tissues including the liver, peritoneal cavity and placenta. Resting NK 
cells circulate in the blood, but, following activation by cytokines, they are capable of 
extravasation and infiltration into most tissues that contain pathogen-infected or malignant 
cells [2-5]. NK cells discriminate between normal and abnormal cells (infected or 
transformed) through engagement and dynamic integration of multiple signaling pathways, 
which are initiated by germline-encoded receptors [6-8]. Healthy cells are protected from NK 
cell-mediated lysis by expression of major histocompatibility complex (MHC) class I ligands 
for NK cell inhibitory receptors [6, 9]. The MHC is a group of highly polymorphic 
glycoproteins that are expressed by every nucleated cell of vertebrates, and that are encoded 
by the MHC gene cluster. The human MHC molecules are termed human leucocyte antigen 
(HLA)-A, B and C molecules. Every NK cell expresses at least one inhibitory receptor that 
recognizes a self-MHC class I molecule. So, normal cells that express MHC class I molecules 
are protected from self-NK cells, but transformed or infected cells that have down-regulated 
MHC class I expression are attacked by NK cells [10].  
 
There are 2 distinct subsets of human NK cells identified mainly by cell surface density of 
CD56. The majority (approximately 90%) of human NK cells are CD56
dimCD16
bright and 
express high levels of FcγRIII (CD16), whereas a minority (approximately 10%) are 
CD56
brightCD16
dim/- [11]. Resting CD56
dim NK cells are more cytotoxic against NK-sensitive 
targets than CD56
bright NK cells [12]. However, after activation with interleukin (IL)-2 or IL-   Introduction 
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12, CD56
bright cells exhibit similar or enhanced cytotoxicity against NK targets compared to 
CD56
dim cells [12-14]. 
 
1.1 Regulation of NK cell function 
The functions of NK cells are regulated by a balance of signals (Fig. 1.1). These are 
transmitted by inhibitory receptors, which bind MHC class I molecules, and activating 
receptors, which bind ligands on tumors and virus-infected cells [15]. These receptors are 
completely encoded in the genome, rather than being generated by somatic recombinations, 
like T- and B-cell receptors.  
 
Figure 1.1: Control of NK cell function by the balance of activating/inhibitory signals. NK cell function is 
regulated by signaling through activation and inhibitory receptors. NK cell activation can occur by means of 
activating receptors, which signal through ZAP70/SYK when immunoreceptor tyrosine-based activating motif 
(ITAM)-containing adaptor proteins, such as DAP12, FcRγ and CD3ζ are activated. Alternatively, the CD28 
molecule or the lectin-like receptor NKG2D coupled to the adaptor protein DAP10, activates NK cells by 
associating with phosphatidylinositol-3-kinase (PI3K) through their binding motifs (YxxM motifs). NK cell 
inhibitory receptors such as Ly49 and KIR contain immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in    Introduction 
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their cytoplasmic domains, which recruit intracellular tyrosine phosphatases such as SHP1 (adapted from 
reference 10). 
 
The NK cell receptors fall into two main structural classes that each contains activation and 
inhibitory members. Receptors in the immunoglobulin superfamily include killer inhibitory 
receptors (KIRs) and leucocyte inhibitory receptors, whereas receptors of the C-type lectin-
like family include lymphocyte antigen 49 (LY49), NKG2D and CD94/NKG2 [16-19]. These 
MHC receptors discriminate among different MHC class I molecules, recognizing specific 
products that are encoded by individual class I alleles. This is in contrast to the highly 
conserved NK-cell immunoglobulin (Ig) and lectin-like receptors, which recognize non-
classical MHC molecules such as HLA-G and HLA-E. These molecules are considerably less 
polymorphic, and differ from classical MHC molecules in their patterns of transcription and 
protein expression, as well as in their immunological functions [20]. An NK cell can express 
several inhibitory and stimulatory receptors at any one time.  
 
1.2 NK cell inhibitory receptors 
Three distinct receptor families that are involved in NK cell recognition of polymorphic MHC 
class I molecules contain immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in their 
cytoplasmic domains (Table 1.1, Fig. 1.1). Following ligation, these ITIMs become 
phosphorylated at tyrosine residues, allowing them to recruit the tyrosine phosphatases SHP1, 
and possibly SHP2. Expression of MHC class I molecules has been shown to protect normal 
and transformed hematopoietic cells from NK-mediated lysis [21, 22] in several graft versus 
leukemia (GVL) models. MHC class I expression has also been associated with protection 
against NK-mediated lysis in patients that have received allogenic bone marrow transplatation 
[23, 24]. The role of MHC class I molecules in NK cell recognition of solid tumors, by 
contrast, has been controversial. Disrupting the interaction between human NK cell KIRs and    Introduction 
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ligands that are expressed by melanoma cells in vivo has been reported to enhance the 
antitumor responses that are mediated by both innate and adaptive immune effector cells [25]. 
In the mouse, Ly49C/I inhibitory receptor blockade increased the NK cell-mediated antitumor 
effects in vitro and in vivo [26]. Rodent Ly49D [27] also activated the activity of NK cells 
against hamster CHO tumor cells [28, 29]. Interestingly, MHC class I-specific receptors that 
inhibit interferon (IFN)-γ production might differ from those that reduce NK cell cytotoxicity 
[30]. 
NK cell receptor  Ligand 
For MHC class I molecules   
Human KIR2DL  HLA-C 
Human CD158/KIR3DL  HLA-Bw4, HLA-A 
Human CD85i/ILT2  HLA class I 
Mouse Ly49  H-2K, H-2D 
For non-classical MHC class I molecules   
CD94/NKG2A 
(mouse: Qa-1b 
HLA-E 
Table 1.1: NK cell inhibitory receptors (adapted from reference 10) 
Human MHC class I molecules are encoded by HLA genes. HLA-E (and its rodent equivalent 
Qa-1b) binds to signal peptides that are derived from the polymorphic classical MHC class I 
molecules (such as HLA-A, B and C). This peptide binding requires the activity of the 
transporter associated with antigen processing (TAP)-1, which stabilizes the HLA-E protein 
and allows it to be transported to the cell surface. After the HLA-E protein is present on the 
cell surface, it can interact with CD94/natural killer group 2A (NKG2A) receptors to inhibit    Introduction 
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NK cells. Some tumor cells no longer express HLA-A, B and C molecules or TAP, preventing 
HLA-E from reaching the cell surface. This allows the tumor cell to become vulnerable to NK 
cell-mediated killing. One in vitro study indicated that CD94/NKG2A ligation could inhibit 
antibody-dependent cellular cytotoxicity (ADCC) that is mediated by NK cells against tumor 
cell lines [31]. 
 
1.3 NK cell activating receptors 
NK cells kill certain cancer cell types in vitro, even though these cells express significant 
levels of MHC class I on their surface. Some activating receptors have been implicated in the 
NK cell recognition of tumors and stressed cells (Table 1.2) [32, 33]. Most of the activating 
NK cell receptors are transmembrane molecules with short intracellular domains that lack 
intrinsic signaling activity. They signal by interacting with transmembrane adaptor molecules, 
such as DAP12, FcRγ and CD3ζ, which contain immunoreceptor tyrosine-based activating 
motifs (ITAMs) (Fig 1.1). 
Receptor Species  Ligand  Signal  transduction 
NKG2D Human 
Mouse 
MIC, ULBP 
Rae-1, H60 
Associated with 
DAP10 and activates 
PI3K pathway 
NKp30 Human Unknown  Associated  with 
ITAM-bearing CD3-
ζ or FcRγ and 
activates 
ZAP70/SYK 
pathway    Introduction 
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NKp46 Human/mouse  Unknown   
NKp44 Human Unknown  Associated  with 
ITAM-bearing 
DAP12 and activates 
ZAP70/SYK 
pathway 
KIR2DS  Human  HLA-C  Same as NKp44 
CD94/NKG2C  Human/mouse  HLA-E/Qa-1  Same as NKp44 
Ly49D Mouse H-2D
d  Same as NKp44 
Ly49H  Mouse  MCMV m157  Same as NKp44 
NKR-P1C (CD161c)  Mouse  Unknown  Same as NKp30 
CD16  Human/mouse  IgG  Same as NKp30 
Co-stimulatory 
molecules 
   
CD28  Human/mouse  CD80, CD86  Activates PI3K 
pathway 
CD27 Human/mouse  CD70 Activates  TRAF 
pathway and 
ZAP70/SYK 
pathway 
2B4 (CD244)  Human/mouse  CD48  Associated with SAP    Introduction 
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Table 1.2: The activation receptors involved in NK cell function. SAP, SLAM-associated 
protein; SYK, spleen tyrosine kinase; TRAF, tumor-necrosis-factor-receptor-associated 
factor; ZAP70, zeta-associated phosphoprotein 70 (adapted from reference 10). 
 
1.3.1 Natural cytotoxicity receptors (NCRs). 
In vitro NK cell-mediated killing of various cancer cell lines can be blocked by combination 
treatment with monoclonal antibodies (mAbs) against three receptors that are responsible for 
the spontaneous cytotoxicity of NK cells. These are NCRs NKp30, NKp44 (only in humans) 
and NKp46 (in mice and humans) [34-36]. The density of NCRs on the surface of NK cells 
varies, and there is a direct correlation between NCR expression by human NK cells and their 
ability to kill tumor cells. NCRs can associate with different signal-transducing adaptor 
proteins. NK cells from mice with gene disruptions in DAP12, FcRγ or CD3ζ have shown 
selective deficiencies in their ability to kill certain tumors [37]. 
 
1.3.2  Natural Killer Group 2D (NKG2D) 
A recently characterized NK cell activating receptor, NKG2D, is a type II disulphide-linked 
dimer with a lectin-like extracellular domain that is expressed on cytolytic cells of the innate 
and adaptive immune systems [38]. NKG2D might be expressed as two isoforms (long and 
short). These forms of NKG2D are associated with the transmembrane adaptor protein 
DAP10 (NKG2Dlong and NKG2Dshort), which binds to and activates phosphatidylinositol-
3-kinase (PI3K) [39], or DAP12 (NKG2Dshort only). Several ligands that bind to mouse and 
human NKG2D are structurally related to MHC class I molecules, and show diverse 
expression patterns and modes of induction (Table 1.3) [38, 40-45]. NKG2D recognizes 
defined antigens that are induced on abnormal cells that are undergoing stress or primary and    Introduction 
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secondary tumors [46, 47], and detection of ligands for NKG2D on stressed cells might 
provide a threshold of activation that allows the killing of abnormal cells.  
 
Ligand Expression  Induction  Structure 
Human     
MICA, 
MICB, α2 
 
Gut epithelium, 
epithelial and non-
epithelial tumors; 
tumor cell lines 
Heat shock; oxidative 
stress; tumor 
transformation; M. 
tuberculosis, E. coli or 
HCMV infection 
Transmembrane protein; 
MHC class-I-related α1 and 
domains 
UL16 
binding 
protein 
(ULBP)1,2,3 
Tumor cell lines  Tumor transformation GPI-anchored  proteins 
Mouse     
Rae-1 
family 
Rae-1α, -1β, 
-1γ, -1δ 
Embryonic tissues; 
tumor cell lines; not 
expressed in most 
normal adult tissues 
Retinoic acid; 
carcinogens; tumor 
transformation 
GP1-anchored proteins; MHC 
class-I-related α1 and α2 
domains 
Rae-1ε Strain-restricted 
expression 
  
H60 Strain-restricted 
expression; activated 
Carcinogens; tumor 
transformation 
Transmembrane protein; 
MHC class-I-related α1 and    Introduction 
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peripheral blood 
leucocytes and 
splenocytes 
α2 domains 
Table 1.3: The ligands for the NKG2D receptor. GPI, gylcosylphosphatidylinositol; HCMV, human 
cytomegalovirus; MHC, major histocompatibility complex (adapted from reference 10). 
 
Transfection of human MHC class I-bearing targets with MHC class I chain-related molecule 
A (MICA) rendered these cells susceptible to NK cell-mediated cytotoxicity in vitro [38] and 
expression of H60 or glycosylphosphatidylinositol (GPI)-linked ligands for mouse NKG2D 
(Rae-1) by MHC class I-expressing tumor cells triggered in vitro NK cell and macrophage 
effector functions [45].  
 
Surveillance that is mediated by NK cell NKG2D might be regulated at the level of ligand 
availability. As only the long transcript of NKG2D is generally constitutively expressed in 
naive NK cells and it associates with DAP10, these cells might require secondary signals from 
other activation receptors, such as NCRs, before they are able to respond to tumors that 
express NKG2D ligands [48]. A better understanding about the ways in which cells respond 
to stress (heat shock, viral infection, retinoids, endotoxin and transformation) and signal their 
stress is required. 
 
1.3.3  NK cell antibody receptors 
NK cells also mediate ADCC by expressing a low-affinity Fc receptor for IgG, FcγRIII 
(CD16). NK cells express different levels of CD16 at various stages of development. The NK 
cell subset CD56
dimCD16
bright is responsible for ADCC [49, 50]. When an antibody binds to 
an antigen, the Fc portion of the antibody is recognized and bound by Fcγ receptors on NK    Introduction 
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cells, leading to activation of NK cells and target cell destruction. This ADCC is the dominant 
component of the activity of antibodies against tumors [10].  
 
1.3.4  NK cell co-stimulatory molecules 
The activation of NK cells also results from the action of co-stimulatory molecules. The NK 
cell activation receptor CD28 interacts with CD80 and CD86 on target cells, which provide 
co-stimulatory signals for human and rodent NK cells [51, 52]. A proportion of human and 
most mouse NK cells constitutively express CD27 on their surface [53, 54]. Stimulation of 
NK cells with CD27 ligand (CD70)-transfected tumor cells could enhance proliferation and 
IFN-γ production of freshly isolated NK cells in the presence of IL-2. In contrast to signals 
that are transmitted by CD28 or NKG2D, NK cell cytotoxicity is not induced by CD27 
ligation. The NK cell surface molecule 2B4 (CD244) also functions as a co-receptor that is 
involved in human NK cell activation [55]. 2B4, together with NTBA, are members of the 
CD2 family. They serve a dual, inhibitory or activating, function depending on the availability 
of downstream regulating elements in their signaling pathway [56, 57]. Their cytoplasmic 
portion bind a small cytoplasmic protein termed signaling lymphocyte activation molecule-
associated protein (SAP) and delivers triggering signals leading to NK cell activation. The 
absence of SAP, a molecular defect typical of X-linked lymphoproliferative (XLP) disease, 
results in binding of SHP-1 phosphatase to 2B4. The consequent SHP-1 activation leads to 
inhibition of the activation pathways thus blocking NK cell function [58]. 2B4 has been 
proposed to provide a fail-safe mechanism to prevent killing of normal autologous cells [59]. 
Interestingly, 2B4 is expressed at the earliert stages of hemopoietic stem cell differentiation, 
while SAP transcripts are absent [59]. Accordingly 2B4 cross-linking by specific mAbs or by 
its ligand CD48 inhibits the function of immature NK cells. Remarkably, CD48 is expressed 
at high densities in bone marrow cells. Thus it is conceivable that 2B4 can provide an    Introduction 
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effective fail-safe mechanism to prevent NK cell-mediated damages to bone marrow cells 
[60]. Other recently identified triggering co-receptors include DNAX accessory molecule 
(DNAM)-1, NKp80 and CD59. NK cells has also been reported to receive early stimulatory 
signals directly through binding of the intercellular adhesion molecule (ICAM)-1 to leucocyte 
function antigen (LFA)-1 expressed on NK cells [61]. 
 
1.3.5 Cytokine and chemokine regulation of NK cells 
Cytokines are crucial natural adjuvants that are involved in the activation of NK cells against 
tumor cells. NK cells can be rapidly activated in the periphery by NK cell stimulatory factors, 
such as IL-12, IFN-α, IFN-β, IL-15 or IL-2. The first indication of their importance came 
from the observations that virus-induced type I IFNs promoted NK cell-mediated cytotoxicity 
and proliferation, and promoted innate defence against viral infections [62]. Very little is 
understood about the IFN and IL-12 signaling pathways in the context of NK cell antitumor 
activity. IL-2 was the first growth and activation factor that was described for NK cells. The 
use of this cytokine in the immunotherapy of cancer has met with some success. IL-15 is also 
a pleiotropic cytokine that is involved in the development and maintenance of NK cells [63, 
64]. In NK cells, the IL-15 receptor includes IL-2/IL-15Rβ and –γ c subunits, which are 
shared with IL-2, and an IL-15-specific receptor subunit, IL-15Rα. While IL-2 is commonly 
used to activate and expand NK cells in vitro, it is conceivable that during the early phases of 
innate immune responses in vivo, IL-15 may exert a predominant role in NK-cell activation 
and function [65-67].  
 
1.4 Biology of Histone deacetylases (HDACs) and Histone acetyltransferases( HATs) 
DNA is packaged into nucleosomes, repeating complexes in chromatin, composed of 
approximately 146 base pairs of 2 superhelical turns of DNA wrapped around an octomer of    Introduction 
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pairs of histones H4, H3, H2a, and H2b. Lysine-rich amino-terminal tails extend from the 
nucleosomes and are responsible for the conformational changes of the DNA [68-71]. 
Modification of the histones includes acetylation, methylation, phosphorylation, and/or 
ubiquitination [70-73]. The “histone code” or “epigenetic code” pertains to the discrete 
modifications of the histones that regulate chromatin function, including the transcription of 
genes. The amino acid tails of histones are subject to posttranslational modification by 
acetylation of lysines, methylation of lysines and arginines, phosphorylation of serines, and 
ubiquitination of lysines. The most extensively studied posttranslational modifications of 
histones are the acetylation and deacetylation of the lysine group. The acetylation status of 
histones and non-histone proteins is determined by HDACs and HATs. HATs transfer acetyl 
group from acetyl coenzyme A to the N terminal end of lysine tail, neutralizing the charge on 
the lysine tail and decreasing the attraction between the histones and DNA, thus allowing 
transcriptional activity [74-77]. HDACs remove the acetyl groups from the lysine residue, 
restoring the positive charge of the lysine causing condensation of the chromatin, thus leading 
to repression of gene expression. In humans, 18 HDAC enzymes have been identified and 
classified, based on homology to yeast HDACs [78-81]. Class I HDACs include HDAC1, -2, 
-3 and -8, which are related to yeast RPD3 deacetylase and have high homology in their 
catalytic sites. Recent phylogenetic analyses suggest that this class can be divided into classes 
Ia (HDAC1 and -2), Ib (HDAC3) and Ic (HDAC8) [82]. Class II HDACs are related to yeast 
Hda1 and include HDAC4, -5, -6, -7, -9 and -10 [80, 81]. This class is divided into class IIa, 
consisting of HDAC4, -5, -7 and -9, and class IIb, consisting of HDAC6, and -10, which 
contain two catalytic sites. All class I and II HDACs are zinc-dependent enzymes. Members 
of a third class, sirtuins, require nicotinamide adenine dinucleotide (NAD
+) for their 
enzymatic activity [79]. Among them, SIRT1 is orthologous to yeast silent information 
regulator 2. Class IV HDAC is represented by HDAC11, which like yeast Hda 1, has 
conserved residues in the catalytic core region shared by both class I and II enzymes [83].    Introduction 
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HDACs are not redundant in function [81, 84, 85]. Class I HDACs are primarily nuclear in 
localization and ubiquitously expressed, while class II HDACs can be primarily cytoplasmic 
and/or migrate between the cytoplasm and nucleus and are tissue-restricted in expression. 
 
1.5 HDAC substrates 
Recent phylogenetic analyses of bacterial HDACs suggest that all four HDAC classes 
preceded the evolution of histone proteins [82]. This suggests that the primary activity of 
HDACs may be directed against non-histone substrates. At least 50 non-histone proteins of 
known biological function have been identified, which may be acetylated and substrates of 
HDACs [81, 84-88]. In addition, two recent proteomic studies identified many lysine-
acetylated substrates [89, 90]. In view of all these findings, HDACs may be better called ‘N-
epsilon-lysine deacetylase’. This designation would also distinguish them from the enzymes 
that catalyze other types of deacetylation in biological reactions such as acylases that catalyze 
the deacetylation of a range of N
α-acetyl amino acids [91]. Non-histone protein targets of 
HDACs include transcription regulators, signal transduction mediators, DNA repair enzymes, 
nuclear import regulators, chaperone proteins, structural proteins, inflammatory mediators, 
and viral proteins. Acetylation can either increase or decrease the function or stability of the 
proteins, or protein-protein interaction [86]. These HDACs substrates are directly or indirectly 
involved in many biological processes, such as gene expression and regulation of pathways of 
proliferation, differentiation and cell death.   
 
1.6 HDACs and HATs in cancer  
Disturbance of the HDAC-HAT dynamic appears to result in the development of cancer. In 
several hematological malignancies, chromosomal translocations result in the development of 
fusion proteins, which exert oncogenic effects through interactions with HDACs.    Introduction 
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Chromosomal translocations 15;17 and 8;21 produce the fusion proteins PML-RARα and 
AML-ETO1, respectively. These proteins recruit HDAC-containing transcriptional repressor 
complexes, resulting in disrupted cell cycle control and the initiation of acute promyelocytic 
and myeloid leukemias. In the development of diffuse large B-cell lymphoma, BCL6, an 
oncogenic protein, recruits a HDAC-containing complex to mediate transcriptional repression 
[92]. Further alterations of the expression and function of HDACs and HATs have been noted 
in malignancies. Mutations in the HAT p300 and cyclic adenosine monophosphate (cAMP) 
response element-binding protein are found in patients with Rubinstein-Taybi syndrome, who 
exhibit developmental delays and increased risk for pediatric malignancies such as 
neuroblastoma (NB) and retinoblastoma [93]. Overexpression of HDACs has been reported in 
various solid tumors. Mice lacking the adenomatosis polyposis coli tumor suppressor gene 
overexpressed HDAC2, which prevented apoptosis in cultured colon cells. Elevated 
expression of HDAC2 has also been detected at high frequency in human colon carcinomas 
[94]. Disrupted activities of HDACs and HATs may potentially result in the hypoacetylation 
of histones in neoplastic cells. Recent evidence suggests that hypoacetylation of lysine 16 of 
histone H4 may represent a common hallmark or signature of human tumor cells. Analyses of 
normal tissues, cancer cell lines, and primary tumors indicated that cancer cells predominantly 
exhibit a loss of acetylated lysine 16 and trimethylated lysine 20 of histone H4. These losses 
were localized to DNA repetitive sequences that were hypomethylated [95]. These findings 
implicate the involvement of HDACs in tumorigenesis and emphasize their potential as 
therapeutic targets. 
 
1.7 Histone deacetylase inhibitors (HDACi)  
HDACi are therapeutic agents that inhibit angiogenesis and induce cell cycle arrest, apoptosis 
and differentiation in cancer cells. They form a new class of antineoplastic agents currently 
being evaluated in clinical trials for the treatment of various solid or hematologic    Introduction 
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malignancies [96-98]. Finnin et al [99] elucidated the crystal structure of the catalytic site of 
an HDAC homolog and have shown that the direct interaction of HDACi with the active zinc 
binding site appears to be required to show inhibitory activity (Fig 1.2).  
 
Figure 1.2: Crystal structure showing binding of SAHA on the catalytic site of an HDAC homolog protein. 
(adapted from reference 99) 
 
Although the HDACi are structurally different, all agents contain a surface recognition site, a 
metal-binding domain that interacts with the zinc pocket, and a linker domain. Because of the 
structural differences, the potency and HDAC inhibitory capabilities are variable among 
classes of HDACi. For example, the enzymatic activity of class III HDACs is not inhibited by 
compounds such as vorinostat (also called suberoylanilide hydroxamic acid, SAHA) or 
trichostatin A (TSA) that inhibit class I and class II HDACs [78]. There are 5 classes of 
HDACi, which include (1) the short-chain fatty acids such as butyrate derivatives and 
valproic acid (VPA); (2) the hydroxamic acids, which include vorinostat (SAHA), PXD101,    Introduction 
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pyroxamide, oxamflatin, cinnamic acid, bishydroxamic acid, LBH589, and scriptaid; (3) 
cyclic tetrapeptides containing a 2-amino-8-oxo-9, 10-epoxy moiety such as trapoxin A; (4) 
cyclic peptides that do not have the amino moiety but that include depsipeptide (FK228); and 
(5) the benzamides such as CI994 and MS 275. Many of these HDACi are in clinical trials 
both as mono-therapy and in combination with cytotoxic and biologic agents.  
 
 
 
Figure 1.3: Representative structures of the main classes of HDACi either from [a] natural sources or [b] 
synthetic (adapted from reference 87)    Introduction 
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1.8 Biologic activities of HDACi 
HDACi have been shown to block the proliferation and the induction of differentiation or 
apoptosis in a wide variety of transformed cells in culture, including cell lines derived from 
both hematologic and epithelial derived malignancies. After inhibition of HDAC activity, 
accumulation of acetylated histones and non-histone proteins is a common upstream event in 
transformed cells; however, the critical downstream events underpinning the antitumor effects 
are poorly understood and will depend in part on the HDAC inhibitory spectrum of the 
specific HDAC inhibitor and resulting substrates of the HDACs affected as well as the 
cellular context of the tumor. The downstream effects can roughly be divided into 2 broad 
categories: transcriptional and non-transcriptional effects. Transcriptional and non-
transcriptional events can result from the HDACi-mediated accumulation of acetylated 
histones or non-histone proteins. Recently, evidence has also indicated that HDACi may 
function to inhibit factors in the angiogenesis pathway [100, 101].  
 
1.8.1 HDACi and cell cycle arrest  
HDACi induce an open chromatin conformation through the accumulation of acetylated 
histones, facilitating the transcription of numerous regulatory genes. Treatment with HDACi 
results in an increase in expression of cyclin-dependent kinase inhibitor p21
waf1 and 
transcriptional repression of cyclin A and D genes, as well as the inhibition of thymidylate 
synthetase, which is involved in DNA synthesis. These events probably contribute to the cell 
cycle arrest at G1/S [102-104]. In normal cells, a G2-phase cell cycle checkpoint is activated 
by treatment with HDACi; however, this checkpoint was found to be defective in several 
tumor cell lines. Loss of this G2 checkpoint caused the tumor cells to undergo an aberrant 
mitosis, resulting in fractured multinuclei and micronuclei, and eventually cell death [105]. It 
is likely that the loss of this G2 checkpoint is somewhat responsible for the selective effects of 
HDACi treatment in tumor cells [98].    Introduction 
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1.8.2 Apoptotic effects of HDACi 
HDACi probably induce apoptosis in tumor cells through the activation of numerous 
mechanisms. It has been hypothesized that treatment with HDACi alters gene expression to 
favor a proapoptotic response [85]. Gene expression profiling of tumor cells treated with 
HDACi showed that proapoptotic genes involved in the extrinsic or death receptor pathway 
[such as Fas or tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)] or the 
intrinsic or mitochondrial pathway (such as bax and bak) are generally up-regulated, whereas 
prosurvival genes such as XIAP and bcl-2 are generally down-regulated. The precise roles of 
the extrinsic versus (vs.) intrinsic pathways in HDACi-induced apoptosis in tumor cells and 
the mechanisms by which they function remain to be discerned.  
 
The production of reactive oxygen species (ROS) appears to play a role in HDACi-induced 
apoptosis as well. HDACi treatment may activate the production of ROS. Alternatively, 
expression of thioredoxin protein 2 (TBP2), a ROS regulatory protein that is expressed at low 
levels in many human cancers, is selectively increased by vorinostat. TBP2 may perhaps bind 
and inactivate thioredoxin, rendering cells more susceptible to oxidative stress [106]. ROS 
scavengers have been shown to suppress apoptosis after treatment with HDACi. 
Hyperacetylation of non-histone proteins may trigger unique apoptotic mechanisms. HDACi 
acetylate and destabilize Hsp90, a non-histone chaperone protein for a variety of 
oncoproteins, including Akt and c-raf, resulting in degradation of these oncoproteins [107].  
Ku70 is a DNA end-joining protein that sequesters the apoptotic protein Bax in the cytoplasm. 
When acetylated after treatment with HDACi, Ku70 releases Bax to the mitochondria to 
induce apoptosis [108, 109]. The HDAC6-specific inhibitor tubacin has been shown to cause 
accumulation of acetylated α-tubulin but not histones. Additionally, tubacin in certain cell    Introduction 
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contexts does not inhibit cell progression but rather may elicit antitumor effects by affecting 
migration or aggresome function [110]. 
 
1.8.3 Antiangiogenic effects of HDACi 
The HDACi have recently been shown to be potent angiostatic agents in vitro and in vivo. In 
both endothelial and tumor cells, HDACi have been shown to down-regulate angiogenesis-
related gene expression. Within cancer cells, HDAC gene expression is thought to be 
transcriptionally activated by hypoxia, resulting in the down-regulation of tumor suppressor 
genes p53 and von Hippel-Lindau. HDACs complex with hypoxia-inducible factor 1α 
(HIF1α) under hypoxic conditions. This leads to increased HIF1α transcriptional activity and 
increased expression of HIF1α target genes, such as vascular endothelial growth factor 
(VEGF) [101, 111, 112]. HDACi have been shown to up-regulate inhibitors of angiogenesis, 
such as p53 and von Hippel-Lindau, and down-regulate angiogenesis-promoting factors, such 
as VEGF and HIF1α, as well as platelet-derived growth factor and basic fibroblast growth 
factor. Furthermore, HDACi down-regulate gene expression of survivin, an apoptotic 
inhibitor, in endothelial cells alone. It therefore appears that the antiangiogenic effects of 
HDACi may be exerted through inhibition of tumor endothelial cell growth as well as through 
altering the expression of genes to produce antiangiogenic effects [101, 111, 112]. The 
antiangiogenic effects of TSA, MS 275 and VPA were also linked to a decrease in the 
generation of nitric oxide (NO) by endothelial cells and a marked reduction in the expression 
of the endothelial nitric-oxide synthase (eNOS) [100, 111]. 
 
1.8.4 HDACi effects in  animal studies 
HDACi have been tested in several animal models including human breast, prostate, lung, 
pancreatic, ovarian, and stomach cancer, melanoma, synovial sarcoma, osteosarcoma, NB,    Introduction 
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medulloblastoma multiple myeloma, and leukemia. Human lymphoma SCID mouse models 
and transgenic mouse models of acute promyelocytic leukemia have also been tested. Overall, 
inhibition of tumor growth was observed with little toxicity. Agents that have been or are 
being currently investigated in phase I and phase II clinical trials include TSA, depsipeptide, 
MS 275, FK 228, and PXD101. The accumulation of acetylated histones caused by HDACi in 
tumor and normal tissues such as spleen and peripheral blood mononuclear cells (PBMCs) 
further suggests that this may be an important biomarker to measure in clinical trials [113]. 
Vorinostat has also been shown to cross the blood-brain barrier in an R6/2HD mouse model 
and increase histone acetylation in the brain [114]. TSA, vorinostat, VPA, phenylbutyrate, and 
depsipeptide have been shown to block angiogenesis in vivo. Anti-proliferative effects may 
thus be exerted through the induction of apoptosis and the interference with tumor’s 
establishment of adequate vascularization [98]. 
 
1.9 Clinical trials with HDACi 
Several HDACi have been investigated in phase I and phase II clinical trials, as single agents 
and in combination with cytotoxic therapies (Table 1.4). SAHA (Vorinostat) and VPA are the 
most studied HDACi.  
 
Class Compound  Phase  of 
Development 
Potency (cells)  HDAC 
target
a 
Hydroxamate  Vorinostat 
(SAHA) 
approved µM  Classes  I,  II 
 PXD101  I/II  µM  Classes  I,  II 
 ITF2357  I nM  Classes  I,  II    Introduction 
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Cyclic peptide  Depsipeptide 
(FK228) 
I/II nM  HDAC1,  -2 
Aliphatic acid  VPA I/II  mM  Classes  I, 
IIa 
  Phenylbutyrate I/II  mM  Classes  I, 
IIa 
Benzamide  MS 275  I/II  µM  HDAC1, -2, 
-3 
Table 1.4: Examples of HDACi in clinical trials. 
a Based on relative sensitivity to HDACi (adapted from 
references 78 and 98) 
 
1.9.1 SAHA (Vorinostat) 
SAHA is a hydroxamic acid inhibitor of HDACs. It has been shown to inhibit the activity of 
HDACs in both class I and class II but does not inhibit the activity of class III HDACs [81, 
115, 116]. SAHA selectivity alters only 2-10% of expressed genes in different transformed 
cells-with the number of genes whose expression increased about equal to the number whose 
expression decreased [117]. Although the mechanisms of SAHA activity are not completely 
understood, it is clear that SAHA induces cell death of transformed cells by selectively 
altering gene expression and the function of proteins that cause caspase-dependent and 
caspase-independent cell death [81, 85, 115, 116, 118-122]. It arrests cell growth of a variety 
of transformed cells in culture at 2.5-5.0 µM [81, 102, 106, 115, 116, 123-125]. Initial trials of 
intravenous vorinostat in patients with refractory hematologic and advanced solid tumors 
showed that this agent was well tolerated, with neutropenia and thrombocytopenia being the 
dose-limiting toxicities in the patients with hematologic malignancies. Vorinostat inhibited 
HDACs and caused the accumulation of acetylated histones in both normal and malignant    Introduction 
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tissues [126]. Subsequently, an oral preparation of vorinostat was tested in phase I trial of 73 
patients with advanced solid tumors. The major dose-limiting toxicities observed were 
anorexia, dehydration, diarrhea, and fatigue. Two of 4 patients with mesothelioma 
experienced partial responses, and a placebo-controlled, randomized phase III study of oral 
vorinostat is now open for patients with mesothelioma in whom treatment with pemetrexed 
has failed [127]. Vorinostat has been partially effective in patients with cutaneous T-cell 
lymphoma (CTCL). In a phase II trial of oral vorinostat in patients with CTCL, 8 of a total of 
33 patients enrolled in the study achieved a partial response, and 14 patients received relief 
from pruritus. The most common grade 3/4 drug-related adverse events were 
thrombocytopenia and dehydration [128]. On October 6, 2006, the U.S. Food and Drug 
Administration granted approval to vorinostat (Zolinza) for the treatment of CTCL in patients 
with progressive, persistent, or recurrent disease on or after 2 systemic therapies.  
 
1.9.2 VPA 
VPA has been used an an anticonvulsant for decades. It suppresses generalized and partial 
seizures, acts as a mood stabilizer, and augments the treatment of migraine and neuropathic 
pain [129]. Recently, cancer treatment has become a new sphere of application for VPA. VPA 
affects the growth and differentiation of a variety of malignant cells in vitro [130]. Similar to 
teratogenicity, the antitumor effect of VPA is independent of the drug’s antiepileptic activity 
because VPA can be modified to exhibit one effect or the other [131]. Antineoplastic activity 
includes an effect on the cell cycle through prolongation of the G1 phase [132]. VPA also has 
a differentiating effect, for example, as shown in NB cells, in which it causes increased 
expression of neural cell adhesion molecules (NCAM), decreased expression of n-myc 
oncoprotein, and morphologic alterations such as neuritogenesis [133-136]. In addition, VPA 
affects the cytoskeleton [137], inhibiting cell motility and tumor metastasis, and demonstrates    Introduction 
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antiangiogenic activity in vitro [100]. The antineoplastic and teratogenic effect of VPA was 
shown to depend mainly on the inhibition of HDAC [135, 138]. VPA inhibits class I HDAC1, 
-2 and -3, and class II HDAC4, -5 and -7 [139]. VPA is now in clinical trial in patients with 
acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) [140, 141, 142]. VPA 
is also used as maintenance therapy for childhood malignant glioma after post-operative 
combined chemotherapy and irradiation [142, 143].  
 
1.10 HDACi and the immune system  
The influence of HDACi on antitumor responses of the innate immune system has been 
described. The effects were mostly based on priming malignant cells with HDACi for 
immune cell-mediated killing. Cinatl et al [144] reported that treatment of NB cells with 0.5 
mM VPA increased their sensitivity to lymphokine-activated killer lysis. Sodium butyrate 
(SB) was used to induce the expression of co-stimulatory/adhesion molecule on AML cells, 
thereby effectively inducing tumor immunity. SB up-regulated CD86 and ICAM-1 expression 
in several AML cell lines and enhanced allogenic mixed leucocyte reaction against HL60 
cells [145]. Cancer cells were also shown to become susceptible to NK cell killing after 
exposure to HDACi like SAHA and FR901228. This susceptibility was due to glycogen 
synthase kinase-3-dependent expression of MICA and MICB [146]. The specific priming of 
malignant cells for innate immune effector mechanisms was again reported to be mediated by 
VPA [147]. Here the authors showed that VPA increased transcription of MICA and MICB in 
hepatocellular carcinoma cells, leading to increased cell surface, soluble and total MIC 
protein expression, as well as increased lysis by NK cells. Furthermore, depsipeptide was 
shown to up-regulate tumor death receptor TRAIL-R2 (DR5) and thereby potentiate NK cell-
mediated tumor killing [148]. 
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HDACi have been reported to comprise a new class of immunosuppressive agents [149]. The 
investigators showed that HDACi FR901228 inhibited CD4 T-cell proliferation in a manner 
which was not caused by apoptosis or decreased viabilty. FR901228 also abrogated the 
characteristic aggregation of T cells following activation without affecting early intracellular 
signals such as tyrosine kinase activity and elevation of intracellular calcium concentration. 
This effect was reported to correlate with diminished activation-induced expression of the 
adhesion molecules, LFA-1 and ICAM-1. Furthermore, HDACi inhibited activation-induced 
CD25 (IL-2 receptor α-chain) and CD154 (CD40 ligand) but not CD69 expression on CD4 
cells [149]. HDAC6-mediated tubulin deacetylation was shown to be involved in CD3 and 
LFA-1 orientation and in the organization of the immune synapse in T lymphocytes [150]. 
However, separate studies ruled out major effects of HDAC inhibition on T-cell proliferative 
and cytotoxic responses and on IFN-γ production [151-153], thus leaving open the possibility 
that other immune cell types may be mostly affected by HDACi and thereby contribute to the 
immunomodulatory properties of these drugs. In this context, recent experiments have shown 
the capacity of a selective HDACi, LAQ824, to specifically modulate gene expression in 
macrophages and dendritic cells (DC) leading to impaired chemokine production and to 
preferential stimulation of Th2 versus Th1 T lymphocytes [154]. Also, VPA and MS 275 
reportly impaired DC differentiation by preventing the acquisition of the DC hallmark CD1a 
and by affecting the expression of co-stimulatory (CD80 and CD86) and adhesion (ICAM-1 
and DC-specific intercellular adhesion molecule 3-grabbing nonintegrin (DCSign)) molecules 
[155]. In addition, the authors demonstrated that macrophage inflammatory protein-
3β/chemokine, motif CC, ligand 19-induced migration, immunostimulatory capacity, and 
cytokine secretion by DCs were profoundly impaired. The observed defects in DC function on 
exposure to HDACi were suggested to reflect the obstruction of signaling through nuclear 
factor kappa B (NFκB), IFN regulatory factor (IRF)-3, and IRF-8 [155]. Reduction of pro-
inflammatory cytokine production was also reported for the HDACi SAHA and ITF2357.    Introduction 
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Human PBMCs stimulated with lipopolysaccharide (LPS) in the presence of SAHA [153] or 
ITF2357 [156] released less tumor necrosis factor (TNF)-α, IL-1-β, IL-12, and IFN-γ. Other 
studies revealed that administration of HDACi to mice ameliorated the autoimmune 
manifestations of graft-versus-host disease, systemic lupus erythematosus, concanavalin A-
induced hepatitis, experimental autoimmune encephalomyelitis, rheumatoid arthritis, and 
colitis [151-153, 157-160]. How the immune effects of HDACi are exactly mediated is 
presently unclear.  
 
1.11 Nucleoside Analogs  
Nucleoside analogs represent a novel group of cytotoxic antimetabolites in the treatment of 
hematological malignancies, solid tumors and viral infections [161-164]. They mimic 
physiological nucleosides and share their metabolic pathways. Most nucleosides enter cells 
via specialized plasma membrane nucleoside transporter (NT) and are phosphorylated by 
cellular kinases to their cytotoxic 5’-triphosphates, which affect RNA and DNA synthesis and 
other metabolic targets. 
 
1.12 1-β-D-arabinofuranosylcytosine (Cytosine arabinoside, cytarabine, araC) 
AraC is one of the most important antileukemic drugs currently available for the treatment of 
AML [165, 166] and large cell lymphoma [167]. AraC was shown to be active against T-
lymphoid H9 cells [168]. Continuous cultivation of T-lymphoid C8166 cells in the presence 
of araC resulted in significantly decreased expression of the major cellular receptor molecule 
CD4 and co-receptor molecule CXCR4 of T-lymphotropic HIV-1 isolates [169]. AraC is a 
deoxynucleoside analog that has to be converted into its active triphosphate derivative 
(araCTP) to exert its cytotoxic effect [170]. AraCTP is then incorporated into the DNA 
causing chain termination, resulting in a block in DNA synthesis and facilitating programmed    Introduction 
  26
cell death [171]. AraC is a hydrophilic molecule and as such requires facilitated diffusion via 
nucleoside-specific membrane transport carriers to enter cells [172, 173]. The human 
equilibrative nucleoside transporter (hENT1) is responsible for 80% of araC influx in human 
leukemic blast cells [173, 174]. Inside the cell, conversion of araC into its monophosphate 
derivative araCMP by deoxycytidine kinase (dCK) is believed to be the rate-limiting step in 
the metabolism of araC [175, 176]. Subsequently, araCMP is phosphorylated into its 
diphosphate derivative araCDP by nucleoside monophosphate kinases, which in turn finally is 
phosphorylated into araCTP by diphosphate kinases [177]. In addition to araC a variety of 
other deoxynucleoside derivatives are active in both hematological and solid malignancies. 
The purine analogs 2-chlorodeoxyadenosine and fludarabine are active against indolent 
lymphoid malignancies and are currently used for the treatment of hairy-cell leukemias and 
chronic and acute leukemias, respectively [178]. The pyrimidine analog gemcitabine has 
activity in various solid malignancies and some hematological disorders [179]. Gemcitabine-
monophosphate prodrug was also shown to be active against thyroid cancer cells in vitro 
[180]. The thymidine (3’-azido-2’,3’-dideoxythymidine, 2’,3’-didehydro-3’-deoxythymidine) 
and deoxycytidine (2’,3’-dideoxycytidine, 2’,2’-difluoro-2’-deoxycytidine) analogs were 
shown to be active against T-lymphoid H9 cells [168]. The cytidine analog 5-aza-2’-
deoxycytidine is a potent hypomethylating agent and has shown to be active in the treatment 
of AML, chronic myeloid leukemia (CML), and MDS [181]. These compounds are activated 
intracellularly via the same metabolic pathway as araC.  
 
1.13 Mechanisms of resistance to araC in transformed cells  
Prolonged, in vitro and in vivo, treatment with araC has resulted in the emergence of drug 
resistant cells with diminished sensitivity to the drug and ultimately contributing to treatment 
failures [166, 182, 183]. Mechanisms of resistance to araC that have been reported  include 
increased inactivation of araC by cytidine deaminase, decreased intracellular permeation,    Introduction 
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decreased cellular activation by dCK, increased degradation of araC-nucleotides by 5’-
nucleotidase, imbalance of cellular deoxynucleotide pools, and increased capability of repair 
of damaged DNA [182-189]. 
 
1.14 Methods for measuring NK cell cytotoxicity  
Fast, sensitive and material-sparing methods to measure NK cytolytic activity, an important 
determinant of NK cell function, are critical for the analysis of physiological functions as well 
as pathological states of the immune system. The gold standard for measuring cell-mediated 
cytotoxicity has been the chromium (
51Cr) [190, 191] or europium (Eu
3+) release assays [191-
194]. However, measurement of target cell lysis by 
51Cr or Eu
3+ release assays is a time-
consuming method requiring labeling of target cells with toxic or radioactive substances that 
present also a drastic manipulation. Moreover, the large number of cells required by these 
methods results in high background values. Several other methods for measuring cell 
cytotoxicity are inconsistent and have numerous shortcomings (table 1.5) [195]. Corey et al 
[196] also extensively described the shortcomings of other assays for measuring cytotoxicity: 
Traditional enzyme release assay like lactate dehydrogenase (LDH) is slow and lack 
sensitivity.  Direct cell counting by dye invasion is tedious and relatively insensitive to small 
amounts of damage; it also suffers from operator error and subjective judgements. Terminal 
deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assays are generally used for 
the study of apoptosis as they are specific for DNA fragmentation, but they are labor-intensive 
and are difficult to interprete. Metabolism-based assays generally involve the addition of a 
chemical which generates a chromophore when it is metabolically processed- this is effective 
for determining the remaining percentage of life cells, but is insensitive to small rates of cell 
death or membrane damage for statistical reasons that are inherent to the method. Due to these 
reasons, the search for other methods that are non-hazardous, easy to perform, and with high 
sensitivity are highly required.    Introduction 
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Table 1.5: Categories of cytotoxicity assays reported in literature
a 
 
a The categories are defined by approach used to measure the results of an interaction between effector cells and 
target cells (adapted from reference 195) 
 
 
 
 
 
  1a: Target cell 
death by 
substance release  
1b: Target cell 
death by cell 
visualization 
2a: Target cell 
survival by 
substance 
uptake/retention  
 
2b: Target cell 
survival by cell 
visualization 
3a: Effector 
activity by 
substance 
release  
3b: Effector 
activity by cell 
visualization 
Parameters 
51chromium, 
europium-DTPA, 
DNA-
fragmentation, 
LDH, KLUK, 
glyceraldehyde 3-
phosphate 
dehydrogenase, 
luciferase, beta-
galactosidase 
PI, 7AAD, 
annexin V, TO-
PRO-iodide, 
decrease in 
forward light 
scatter or 
antibody 
binding 
 
 
 
MTT, 4-Methyl-
umbelliferyl-
heptanoate, 
alamarBlue, 
gammaglutamyl, 
transpeptidase 
PI, 7AAD 
exclusion, 
scatter 
granzyme B  conjugate 
formation 
Methods gamma  camera, 
fluorimetry, 
ELISA, 
luminescence, 
photometry, 
Elispot 
 
flow cytometry, 
fluorimetry 
colorimetry, 
fluorimetry, 
photometry 
flow 
cytometry 
ELISA 
Elispot 
flow 
cytometry 
Advantage  all target death 
detected unless 
substance 
reuptake by 
surviving targets 
and/or effectors 
 
easy handling, 
direct 
visualization, 
reduced cell 
manipulation 
unless stained 
before coculture 
 
reduced 
manipulation of 
cells unless marked 
before coculture 
easy handling, 
direct 
visualization 
detection of 
effector 
molecule of 
cytotoxic 
activity 
visualization 
of conjugate 
formation 
Disadvantage extensive  cell 
manipulation, 
difficulty with 
labeling, some 
radioactivity, cell 
losses due to 
washing, in part 
transduction, 
target cell purity 
of >80% required 
escape from 
detection by 
disintegration of 
cells, gating 
difficulty due to 
change in 
properties of 
dead cells 
uptake of substance 
by effectors not 
easy to quantify, 
target cells in good 
condition with 
sufficient metabolic 
activity needed, 
target cell purity of 
>80% required 
dependent on 
precise sample 
preparation and 
measurement 
restricted to 
granule 
dependent 
activity 
conjugate 
formation not 
equal to killing    Introduction 
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1.15 Aim of research 
Adequate measurement of cytolytic activity of NK cells is necessary to determine their 
functional status. This research focuses firstly on the establishment of a highly sensitive, safe, 
material saving, easy to perform, and reliable method for the measurement of NK cytolytic 
activity. Two research projects were then investigated using the established method.  
 
NK cells as components of the innate immunity substantially contribute to the elimination of 
virus-infected cells as well as antitumor immune response [60]. Modulation of immune 
responses which may be important for NK cell activity through epigenetic mechanisms such 
as acetylation and deacetylation has been studied by some groups. Most of these studies were 
based on the effects of HDACi on the expression of co-stimulatory/adhesion molecules (e.g. 
CD86 and ICAM-1), tumor death receptors like TRAIL-R2 (DR5) and ligands for the 
activating receptors of NK cells (e.g. MICA, MICB, ULBP 1-3) in leukemic and tumor cell 
lines respectively (see section 1.10) [145-148]. Other studies were based on the direct effect 
of HDACi on pro-inflammatory cytokine production in T cells, DCs, and PBMCs (section 
1.10) [149-156]. On the other hand, nothing has been reported in literature on the direct effect 
of HDACi on NK cell cytotoxic activity. The first research studied by using the established 
method for measuring NK cell cytotoxicity focuses on the direct effect of two HDACi, SAHA 
and VPA, on the cytolytic activity of NK cells. Since cytotoxic activity of NK cells is a 
complex process that requires adhesion to target cells, synapse formation, and signal 
transduction leading to granule polarization and exocytosis, it is imperative to determine the 
steps effected by HDACi. Towards this end, the effects of SAHA and VPA on (1) the surface 
expression pattern of adhesion molecule (LFA-1), IL-2 receptors (CD25, CD122, CD132), 
NK cell triggering receptors (NKp30, NKp44, NKp46, NKG2D, DNAM-1), NK cell 
inhibitory receptors (NKG2A, KIR) (2) intracellular perforin and Granzyme B expression (3)    Introduction 
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activation of NFκB signaling and (4) granule exocytosis and IFN-γ production in NK cells 
were investigated. 
 
As mentioned in section 1.11, chemotherapy is insufficient in the clearance of hematological 
malignancies and solid tumors. Although the treatment of leukemia like AML has improved, 
patients that attained complete remission were shown to relapse from minimal residual 
disease cells that apparently survived chemotherapy [197], giving rise to a more resistant 
leukemia. Resistance to chemotherapy therefore remains a major obstacle in the treatment of 
leukemia and solid tumors. 
 
The second aspect of this research studied by using the established method for measuring NK 
cell cytotoxicity focuses on NK cell cytotoxicity of drug-resistant leukemic cell lines. For this 
purpose the expression of ligands of NK cell activating and inhibitory receptors on parental 
and araC-resistant H9 and Molt-4 cell lines as well as their function in NK cell-mediated 
cytolytic activity was investigated. The possible mechanism involved in the expression 
pattern of the ligands was also studied.     Materials and Methods 
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2.0  Materials and Methods 
2.1 Materials 
2.1.1 Chemicals 
Product Manufacturer 
Absolute Ethanol  J.T. Baker, Stuttgart, Germany 
Acrylamide Gel 30  Roth, Karlsruhe, Germany 
Ammoniumpersulphate (APS)  Sigma-Aldrich, St. Louis, USA 
Antipain  Sigma-Aldrich, St. Louis, USA 
Aprotinin  Sigma-Aldrich, St. Louis, USA 
Aqua ad injectabila  Delta Select GmbH, Dreieich, Germany 
Aqua bidest.  Milli-Q biocel, Millipore GmbH, Eschborn, 
Germany 
BAY11-7085  Calbiochem, Darmstadt, Germany 
β-Mercaptoethanol  Sigma-Aldrich, St. Louis, USA 
Biocoll Separating Solution (Ficoll)  Biochrom AG, Berlin, Germany 
Bovine Serum Albumin (BSA)  Bovine Serum Albumin, Fraction V, PAA 
Laboratories, Pasching, Austria 
Chloroform  Merck, Darmstadt, Germany 
Chymostatin  Sigma-Aldrich, St. Louis, USA 
Cytofix/Cytoperm  BD Biosciences, San Jose, USA 
Cytosine ß-D-Arabinofuranosylcytosine 
(Cytarabine; araC) 
Sigma-Aldrich, St. Louis, USA 
Diethylpyrocarbonate (DEPC) water, 
molecular biology grade 
Eppendorf, Hamburg, Germany     Materials and Methods 
  32
Dimethylformamide  Fisher Scientific, Leicestershire, UK 
Dimethylsulphoxide (DMSO)  Sigma-Aldrich, St. Louis, USA 
Ethylenediaminetetraacetic acid (EDTA)  Merck, Darmstadt, Germany 
FACS Clean  BD Biosciences, San Jose, USA 
FACS Flow  BD Biosciences, San Jose, USA 
FACS Rinse  BD Biosciences, San Jose, USA 
Fetal Bovine Serum (FBS)  Sigma-Aldrich, St. Louis, USA 
Glycine  Roth, Karlsruhe, Germany 
HCl  AppliChem GmbH, Darmstadt, Germany 
Hepes  J.T. Baker, Stuttgart, Germany 
Human Serum  Blood Bank of the German Red Cross, 
Frankfurt, Germany 
Incidin Perfect  Ecolab, Duesseldorf, Germany 
Incidin PLUS  Ecolab, Duesseldorf, Germany 
Iscove’s Modified Dulbecco Medium 
(IMDM) 
Biochrom AG, Berlin, Germany 
Isopropanol  Riedel-de Haeen, RdH, Laboratory 
Chemicals, Seelze, Germany 
Laemmli  Bio-Rad Laboratories, Munich, germany 
Leupeptin  Sigma-Aldrich, St. Louis, USA 
L-Glutamin  Sigma Chemical Co., St. Louis, USA 
MgCl2 solution pack  Applied Biosystems, Darmstadt, Germany 
MTT  Serva Electrophoresis GmbH, Heidelberg, 
Germany 
NaCl  Roth, Karlsruhe, Germany     Materials and Methods 
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Non-fat milk  Roth, Karlsruhe, Germany 
Okadaic acid  Sigma-Aldrich, St. Louis, USA 
Orthovanadate (sodium orthovanadate)  Sigma-Aldrich, St. Louis, USA 
Paraformaldehyde  Sigma Chemical Co., St. Louis, USA 
PD98059  Merck, Darmstadt, Germany 
Penicillin Gruenethal  GmbH,  Aachen,  Germany 
Pepstatin A  Sigma-Aldrich, St. Louis, USA 
PermWash  BD Biosciences, San Jose, USA 
Phenylmethylsulfonylfluoride (PMSF)  Sigma-Aldrich, St. Louis, USA 
Phosphate buffered saline (PBS)  Sigma-Aldrich, St. Louis, USA 
Ponceau S solution  Sigma-Aldrich, St. Louis, USA 
Prestained protein marker  Biolabs, Ipswich, USA 
Propidium iodide (PI) stock solution  Sigma-Aldrich, St. Louis, USA 
Reagent A  Bio-Rad laboratories, Munich Gemany 
Reagent B  Bio-Rad Laboratories, Munich Gemany 
Reagent S  Bio-Rad Laboratories, Munich Gemany 
Sodium acetate  Riedel-de Haeen, RdH, Laboratory 
Chemicals, Seelze, Germany 
Sodiumdodecylsulphate (SDS)  AppliChem, Darmstadt, Germany 
Sodium hydrogen carbonate (NaHCO3)  Merck, Darmstadt, Germany 
Sodium hydroxide (NaOH)  Merck, Darmstadt, Germany 
Streptomycin sulphate  Sigma-Aldrich, St. Louis, USA 
Suberoylanilide hydroxamic acid (SAHA)  Alexis Biochemicals, Gruenberg, Germany 
TEMED (N,N,N’,N’-
Tetramethylethylenediamine) 
Roth, Karlsruhe, Germany     Materials and Methods 
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TRI® Reagent  Sigma-Aldrich, St. Louis, USA 
Tris SAFC,  Andover,  UK 
Tris base  Sigma-Aldrich, St. Louis, USA 
Triton X-100  Merck, Darmstadt, Germany 
Trypsin  Difco, Hamburg, Germany 
Trypsin inhibitor  Sigma-Aldrich, St. Louis, USA 
Tween 20  AppliChem, Darmstadt, Germany  
Valproic acid (VPA) (2-Propyl-Pentanoic 
acid sodium salt) 
Sigma-Aldrich, St. Louis, USA 
Vincristine (VCR)  Sigma-Aldrich, St. Louis, USA 
 
2.1.2 Media, Buffer and Solution 
2.1.2.1 Media, buffer and cell culture solution 
PBS 10x concentrate: 
95.5 g dry medium was dissolved in 1000 ml Aqua bidest. The solution was then autoclaved. 
PBS 1x concentrate: 
50 ml PBS from 10x concentrate was diluted in 450 ml Aqua bidest. 
Trypsin solution: 
0.2% trypsin and 0.02% EDTA were dissolved in 1000 ml PBS. Aliquots were made and 
stored at -20°C. 
Sodium bicarbonate solution 7.5%: 
75 g NaHCO3 were dissolved in 1000 ml Aqua bidest. The resulting solution was sterile 
filtered and stored at 4°C. 
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L-Glutamine 0.2 M: 
29.2 g L-glutamine were dissolved in 1000 ml Aqua bidest. The resulting solution was sterile 
filtered and stored at -20°C. 
Penicillin/Streptomycin solution: 
10
6 IE penicillin and 10 g streptomycin sulphate were dissolved in 1000 ml Aqua bidest. The 
resulting solution was sterile filtered and stored at -20°C. 
IMDM basic medium: 
17.26 g IMDM dry medium were dissolved in 1000 ml Aqua bidest and sterile filtered using a 
0.22 µm filter. Medium was stored at 4-8°C for a maximum of 4 months. 
 
IMDM culture medium: 
1% from Penicillin/Streptomycin solution 
2% L-Glutamin 0.2 M 
4% from sodium bicarbonate solution 
10% FBS or 20% FBS, depending on cell to be cultured 
83% or 73% IMDM Basic Medium depending on cell to be cultured 
 
Cytotoxicity assay medium: 
1% from Penicillin/Streptomycin solution 
2% L-Glutamin 0.2 M 
4% from sodium bicarbonate solution 
1% heat inactivated FBS  
92% IMDM Basic Medium 
     Materials and Methods 
  36
2.1.2.2 Buffer and solution for fluorescent-activated cell sorting (FACS) 
FACS buffer (Wash buffer): 
2.5 g BSA were dissolved in 500 ml 1x PBS. The buffer was sterile filtered and stored at 
room temperature. 
Paraformaldehyde fixation solution 1%: 
10 g paraformaldehyde were dissolved in a mixture containing 400 ml Aqua bidest and 600 
ml 1x PBS. The resulting solution was sterile filtered, portioned and stored at -20°C. Thawed 
aliquots were stored at 4°C.   
 
2.1.2.3 Buffer for cell separation (MACS buffer): 
0.5% BSA and 2 mM EDTA were dissolved in 500 ml 1x PBS. The resulting solution was 
sterile filtered using a 0.22 µm filter and stored at 4-8°C. 
 
2.1.2.4 Buffer for cDNA (RTA buffer): 
4000 ml RTA buffer was prepared by mixing 800 µl MgCl2, 400 µl 10x PCR buffer II, 40 µl 
DNA polymerization mix (200 µM) and 2760 µl DEPC water together. This volume is 
enough for 25 cDNA dilutions. Storage 4-8°C.  
 
2.1.3 Antibodies and cytokines 
2.1.3.1 Monoclonal antibody  
Antiboby Clone  Manufacturer 
AffiniPure F(ab’)2 fragment 
goat anti-mouse IgG, F(ab’)2 
fragment specific 
 Jackson  ImmunoResearch 
Laboratories  West Grove, 
USA)     Materials and Methods 
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Allophycocyanin (APC)-
conjugated mouse anti-
human CD3 
SK7  BD Biosciences, San Jose, 
USA 
Anti-human MICA/MICB  BAMO1  Immatics Biotechnologies, 
Tuebingen, Germany 
Anti-human ULBP-1  170818  R&D Systems, Wiesbaden, 
Germany 
Anti-human ULBP-2  165903  R&D Systems, Wiesbaden, 
Germany 
Anti-human ULBP-3  166510  R&D Systems, Wiesbaden, 
Germany 
Anti-mouse IgG peroxidase 
conjugated 
  Calbiochem, San Diego, 
USA 
Anti-rabbit IgG peroxidase 
conjugated 
  Calbiochem, San Diego, 
USA 
Fluorescein isothiocyanate 
(FITC)-conjugated mouse 
anti-human CD11a/LFA-1 
G43-25B  BD  Biosciences, San Jose, 
USA 
FITC-conjugated mouse anti-
human HLA Class 1 
W6/32  Biosource, Camarillo, USA 
FITC-conjugated isotype 
specific goat anti mouse  
  BD Biosciences, San Jose, 
USA 
FITC-conjugated isotype 
specific isotype control 
  BD Biosciences, San Jose, 
USA 
Mouse monoclonal to polio  D171  Abcam, Cambridge, UK     Materials and Methods 
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virus receptor (PVR) 
Phycoerythrin (PE)-
conjugated anti-human 
KIR/CD158 
180704 R&D  Systems,  Wiesbaden, 
Germany 
PE-conjugated anti-human 
CD 132/common γ chain 
31134 R&D  Systems,  Wiesbaden, 
Germany 
PE-conjugated anti-human 
IL-2 Rβ (CD122) 
27302 R&D  Systems,  Wiesbaden, 
Germany 
PE-conjugated anti-human 
NCAM/CD56 
301040 R&D  Systems,  Wiesbaden, 
Germany 
PE-conjugated anti-human 
IL-2 Rα (CD25) 
24212 R&D  Systems,  Wiesbaden, 
Germany 
PE-conjugated isotype 
specific goat F(ab’)2 anti-
mouse IgG 
 R&D  Systems,  Wiesbaden, 
Germany 
PE-conjugated isotype 
specific isotype control 
 R&D  Systems,  Wiesbaden, 
Germany 
PE-conjugated granzyme B  GB11  Abcam, Cambridge, UK 
PE-conjugated Perforin  δG9  BD Biosciences, San Jose, 
USA 
PE-conjugated anti-human 
NKp30 
Z25 Beckman  Coulter,  Marseille, 
France 
PE-conjugated anti-human 
NKp44 
Z231 Beckman  Coulter,  Marseille, 
France 
PE-conjugated anti-human  BAB281  Beckman Coulter, Marseille,     Materials and Methods 
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NKp46 France 
PE-conjugated mouse anti-
human NKG2A 
Z199 Beckman  Coulter,  Marseille, 
France 
Purified human NKp30  Z25  Beckman Coulter, Marseille, 
France 
Purified human NKp44  Z231  Beckman Coulter, Marseille, 
France 
Purified human NKp46  BAB281  Beckman Coulter, Marseille, 
France 
Purified human NKG2D  1D11  BD Biosciences, San Jose, 
USA 
Purified mouse anti-human 
CD226 (DNAM-1) 
DX11  BD Biosciences, San Jose, 
USA 
 
2.1.3.2 Antibodies for Western Blot 
Akt antibody (rabbit polyclonal IgG)  Cell Signaling, Beverly, USA 
Anti-β-actin, clone AC-15, mouse 
monoclonal IgG 
Sigma-Aldrich, St. Louis, USA 
Goat anti-mouse IgG, H & L chain specific 
(peroxidase conjugate) 
Merck, Darmstadt, Germany 
Goat anti-rabbit IgG, H & L chain specific 
(peroxidase conjugate) 
Merck, Darmstadt, Germany 
Phospho-Akt (Ser473) (193H12; rabbit 
monoclonal IgG) 
Cell Signaling, Beverly, USA 
Phospho-p44/42  (pERK1/2) MAP Kinase  Cell Signaling, Beverly, USA     Materials and Methods 
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(Thr202/Tyr204) Antibody (rabbit polyclonal 
IgG)  
p44/42 MAP (ERK1/2) Kinase Antibody 
(rabbit polyclonal IgG) 
Cell Signaling, Beverly, USA 
 
2.1.3.3 Cytokines 
Recombinant human IL-2  Cell concept, Umkirch, Germany 
 
2.1.4 Reagents for SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
2.1.4.1 Resolving gel composition (for 2 gels) 
12 ml  10% 
H2O 3.5  ml 
30% Acrylamide  4.0 ml 
1 M Tris/HCl pH 8.8  4.5 ml 
10% SDS  120 µl 
10% APS  90 µl 
TEMED 15  µl 
 
2.1.4.2 Stacking gel composition (for 2 gels) 
3.5 ml  5% 
H2O 2.48  ml 
30% Acrylamide  0.55 ml 
1 M Tris/HCl pH 6.8  0.44 ml 
10% SDS  35 µl 
10% APS  24 µl     Materials and Methods 
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TEMED 4.5  µl 
 
2.1.4.3 Protease inhibitor mix (PIM) 
15 mM Antipain pH 7.4  1 mg Antipain dissolved in 1 ml Hepes 
15 mM Aprotinin pH 7.4  1 mg Aprotinin dissolved in 1 ml Hepes 
15 mM Chymostatin pH 7.4  1 mg Chymostatin dissolved in 200 µl 
DMSO + 800 µl Hepes 
15 mM Leupeptin pH 7.4  1 mg Leupeptin dissolved in 200 µl DMSO + 
800 µl Hepes 
15 mM Pepstatin A pH 7.4  1 mg Pepstatin A dissolved in 200 µl DMSO 
+ 800 µl Hepes 
15 mM Trypsin inhibitor pH 7.4  1 mg Trypsin inhibitor dissolved in 1 ml 
Hepes 
 
2.1.4.4 Electrophoresis and transfer buffers 
Electrophoresis Buffer (10x), pH 8.3  0.25 M Tris Base 
In 1000 ml aqua bidest., stored at 4°C  1.9 M Glycine 
 1%  SDS 
  
Transfer Buffer (10x), pH 8.3  0.25 M Tris Base 
In 1000 ml aqua bidest., stored at 4°C  1.9 M Glycine 
 20%  Methanol 
 
2.1.4.5 Wash and blocking buffers 
Wash Buffer (10x), pH 7.5  500 mM Tris/Cl     Materials and Methods 
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In 1000 ml aqua bidest., stored at Room 
temperature 
1.5 M NaCl 
  0.3% Tween 20 
  
Blocking Buffer (1x)  50 ml from 1 M Tris/Cl (pH 7.5) 
In 1000 ml aqua bidest., stored at Room 
temperature 
200 mM NaCl 
  0.05% Tween 20 
  3% BSA (or 5% non-fat milk) 
 
2.1.5 PCR 
2.1.5.1 Reagents for reverse transcription polymerase chain reaction (RT-PCR) 
MuLV Reverse Transcriptase N808-008  Applied Biosystems, Licoln, USA 
RNase Inhibitor N808-0119    Applied Biosystems, Licoln, USA 
Absolute TM QPCR SYBR Green ROX (500 
nM) Mix AB-1163/a (PCR) 
 
ABgene, Hamburg, Germany 
DNA-Polymerization Mix 20 mM/dNTP 
(RT-PCR) 
Pharmacia, Ratingen, Germany 
MgCl2 Solution 25 mM N808-0010 (RT-
PCR) 
Applied Biosystems, Licoln, USA 
Random Hexamers 50 µM N808-0127 (RT-
PCR) 
Applied Biosystems, Licoln, USA 
10x PCR Buffer II N808-0010 (RT-PCR)  Applied Biosystems, Licoln, USA 
QuantiTect Probe PCR Kit (1000) 204345 QIAGEN,  Hilden,  Germany     Materials and Methods 
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(PCR) 
QuantiTect SYBR Green PCR Kit (1000) 
204145 (PCR) 
QIAGEN, Hilden, Germany 
All enzymes were stored at -20°C 
 
2.1.5.2 Primers 
Assay Name  Primer design  Forward Primer  Reverse Primer 
β-actin  In-house  5’-cgc gag aag atg acc 
cag  at-3’ 
5’-cag agg cgt aca 
ggg ata gca-3’ 
NKp30  Castriconi et al. 
2003 [198] 
5’-tga tca tgg tcc atc 
cag ga-3’ 
5’-aat ggc cag tct ccc 
ttg g-3’  
NKp46  Castriconi et al. 
2003 [198] 
5’-ggc aga atc tga gcg 
atg tct t-3’ 
5’-gct ttt cct ttg gaa 
cca tga a-3’ 
ULBP-2 Borchers  et  al. 
2006 [199] 
5’-ccc tgg gga aga aac 
taa atg tc-3’ 
5’-act gaa ctg cca aga 
tcc act gct-3’ 
ULBP-3 Borchers  et  al. 
2006 [199] 
5’-aga tgc ctg ggg aaa 
aca act g-3’ 
gta tcc atc ggc ttc aca 
ctc aca-3’ 
 
 
2.1.6 Commercial Kits 
Human IFN-γ ELISA  R&D Systems, Wiesbaden, Germany 
Human Perforin ELISA  Diaclone Research, Besancon Cedex, France 
Human Granzyme B ELISA  Diaclone Research, Besancon Cedex, France 
TransAM
TM NFκB (p50 and p65)  Active Motif, Carlsbad, USA 
Nuclear extract kit  Active Motif, Carlsbad, USA     Materials and Methods 
  44
aCella-Tox
TM bioluminescence cytotoxicity 
assay kit 
Cell Technology, Mountain View, USA 
MACS human NK cell isolation kit II  Miltenyi Biotec, Bergisch Gladbach, 
Germany 
 
 
2.1.7 Diverse materials 
Tip One Filter Tips, 0.1-10 µl, 1-100 µl, 1-
200 µl, 100-1000 µl 
Starlab GmbH, Ahrensburg, Germany 
5 ml Polystyrene Round Bottom Tube  Becton Dickinson Bioscience Discovery 
Labware, Bredford, USA 
Costar Stripette 5 ml, 10 ml, 25 ml, 50 ml  Corning incorporated Corning, New York, 
USA 
Microtubes 0.5 ml, 1.5 ml  Sarstedt, Nuernbrecht, Germany 
Combitips plus 1 ml, 5 ml, 10 ml, 50 ml  Eppendorf, Hamburg, Germany 
1.8 ml, 5 ml, Nunc Cryotube
TMVials  Nunc Brand Products Nalge Nunc 
International, Roskilde, Denmark 
2 ml Pipette  Falcon BD Labware, NY, USA 
TipOne Extended Length, Natural Tips 1-10 
µl, 1-200 µl, 100-1000 µl 
Starlab GmbH, Ahrensburg, Germany 
Culture flasks, different sizes with filter  Nunc Brand Products Nalge Nunc 
International, Roskilde, Denmark 
Culture flasks, different sizes without filter  Greiner bio-one, Frickenhausen, Germany, 
Falcon BD Labware, NY, USA 
96-well plate transparent  Greiner bio-one, Friekenhausen, Germany     Materials and Methods 
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96-well plate white bottom  Greiner bio-one, Frickenhausen, Germany 
6-,12-, 24-well plate  Falcon BD Labware, NY, USA 
Falcon Tubes, 15 ml, 50 ml  Greiner bio-one, Frickenhausen, Germany 
Hand gloves, Peha-Soft Powder free  Paul Hartmann AG, Heidenheim, Germany 
Nitrile hand gloves NOBA Glove®Nitril  NOBA Verbandmittel GmbH u. CoKG, 
Wetter, Germany 
Safe Lock Tubes 1.5 ml  Eppendorf, Hamburg, Germany 
Microamp 96-well Rention Plate, optical 
plate P7N 4306737 
Applied Biosystems, Foster City, USA 
Microamp Optical Adhesive Film  Applied Biosystems, Foster City, USA 
Scalpel   Feather Safety Razor CO. LTD, Osaka, 
Japan 
Safeseal Tips  Biozym Diagnostic GmbH, Hess.Oldenburg, 
Germany 
 
 
2.1.8 Laboratory equipments and software 
Adobe PhotoShop CS2  Adobe Systems incorporated, San Jose, USA 
Analysis scale  Sartorius GmbH, Goettingen, Germany 
Autoclave  Systec GmbH Labortechnik, Wettenberg, 
Germany 
Camera CC12  Soft Imaging Systems 
Centrifuges  Hettich Zentrifugen, Tuttlingen, Germany; 
Eppendorf, Hamburg, Germany 
Cooling Chamber  Viesmann, Germany     Materials and Methods 
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CO2 incubator  Binder, Tuttlingen, Germany 
Counter  Carl Roth GmbH & Co., Karlsruhe, Germany
Counting chamber  W. Schreck, Hofheim, Germany 
Cell Quest
Pro  Becton Dickinson, San Jose, USA 
Counter  Carl Roth GmbH & Co., Karlsruhe, Germany
Cover slide  Superior, Lauda-Koenigshofen, Germany 
FACSCalibur
TM  Becton Dickinson, San Jose, USA 
Glass Flasks- different sizes  Schott, Mainz, Germany 
Glomax 96 Microplate Luminometer  Turner BioSystems, California, USA 
Ice Machine  Scotsman, Milan, Italy 
Incubator without CO2  Heraeus, Hanau, Germany 
Magnet Midi MACS  Miltenyi Biotec, Bergisch-Gladbach, 
Germany 
Magnet stirer  GLW Gesellschaft für Laborbedarf GmbH, 
Wuerzburg, Germany 
Microscope IX71/CKX41  Olympus, Hamburg, Germany; 
Carl Zeiss, Goettingen, Germany 
Microsoft Office 2007  Microsoft Corporation, Redmond, USA 
Millipore  Millipore, Eschborn, Germany 
Mini-PROTEAN® II Electrophoresis Cell  Bio-Rad Laboratories, Munich, Germany 
Multi Magnet Stand  Miltenyi Biotec, Bergisch-Gladbach, 
Germany 
Multicanal pipette  Eppendorf, Hamburg, Germany 
Multipipette  Eppendorf, Hamburg, Germany 
Nitrocellulose membrane  Schleicher & Schuell, Dassel, Germany     Materials and Methods 
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7900HT Fast Real-Time PCR System with 
standard 96-well block module 
Applied Biosystems, Licoln, USA 
pH-Meter  WTW GmbH, Germany 
Photospectrometer GENios Plus  TECAN Deutschland GmbH, Crailsheim, 
Germany 
Photospectrometer Gene Quant II  Pharmacia Biotech, Amersham Biosciences, 
Freiburg, Germany 
Pipetteboy IBS  Integra  Bioscience Pipetboy acu, 
Fernbach, Germany 
Pipettes 0.5-10 µl, 2-20 µl, 10-100 µl, 50-
200 µl, 100-1000 µl 
Eppendorf, Hamburg, Germany ; BioHit 
Deutschland GmbH ; Gilson, Middleton, 
USA 
Reference Manager® 10  Thomson Research Soft., Carlsbad USA 
Refrigerators and Freezers  Liebherr-Holding GmbH, Bieberach, 
Germany; 
Bosch, Stuttgart, Germany 
Scale  Mettler GmbH, Giessen, Germany 
Sterile flow  Heraeus, Hanau, Germany; Kendro, Vienna, 
Austria; NUAIRE, Plymouth, USA; 
Microflow Biological Safety Cabinett 
Thermomixer  Eppendorf, Hamburg, Germany 
Vortexer  Heidolph Instruments, Schabach, Germany 
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2.1.9 Target cell lines 
2.1.9.1 Cell lines purchased from cell bank 
Cell line  Cell type  Origin  Cell number  Culture 
medium 
P-815 Mouse 
mastocytoma 
Established from the 
mastocytoma tumor of a 
DBA/2 mouse treated with 
methylcolanthrene 
DSMZ: 
ACC 1 
IMDM with 
10% 
FBS+supple
ments 
Jurkat, clone 
E6-1 
Human acute T 
cell leukemia 
The line was cloned from 
Jurkat-FHCRC cells 
ATCC No. 
TIB-152 
IMDM with 
10% 
FBS+supple
ments 
HL-60 Human 
Promyelocytic 
leukemia 
Established from peripheral 
blood leucocytes by 
leukopheresis from a 36-
year-old Caucasian female 
with acute promyelocytic 
leukemia. 
ATCC No. 
CCL-240 
IMDM with 
10% 
FBS+supple
ments 
K562 Human 
erythroleukemia 
Established from the pleural 
effusion of a 53-year-old 
female with myelogenous 
leukemia in terminal blast 
crises. 
ATCC No. 
CCL-243 
IMDM with 
20% 
FBS+supple
ments 
H9 Human  T-cell 
lymphoma 
H9 is a clonal derivative of 
HuT 78, a human T-cell 
ATCC No. 
HTB-176 
IMDM with 
10%     Materials and Methods 
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line derived from peripheral 
blood of a patient with 
sezary syndrome 
FBS+supple
ments 
Molt-4 Human  acute 
lymphoblastic 
leukemia 
Molt-4 is a suspension 
culture derived from the 
peripheral blood of a 19-
year-old male with acute 
lymphoblastic leukemia in 
relapse. 
ATCC No. 
CRL 1582 
IMDM with 
10% 
FBS+supple
ments 
C8166 Human  T-cell 
leukemia 
Derived by fusion of 
primary umbilical cord 
blood cells with HTLV-1 
producing line from adult T 
cell leukemia lymphoma 
patient. 
ECACC 
88051601 
IMDM with 
10% 
FBS+supple
ments 
PC-3   Human Prostate 
adenocarcinoma 
PC3 was initiated from a 
grade IV prostatic 
adenocarcinoma from a 62-
year-old male Caucasian 
ATCC No. 
CRL 1435 
IMDM with 
10% 
FBS+supple
ments 
LNCaP (clone 
FGC) 
Human metastatic 
prostate 
adenocarcinoma 
This strain was isolated 
from a needle aspiration 
biopsy of the left 
supraclavicular lymph node 
of a 50-year-old Caucasian 
male (blood type B+) with 
ATCC No. 
CRL-1740 
IMDM with 
10% 
FBS+supple
ments     Materials and Methods 
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confirmed diagnosis of 
metastatic prostate 
carcinoma  
DU145 Human  prostate 
carcinoma, 
metastasis to brain 
DU145 was isolated from a 
lesion in the brain of a 
patient with widespread 
metastatic carcinoma of the 
prostate and a 3-year 
history of lymphocytic 
leukemia 
ATCC No. 
HTB-81 
IMDM with 
10% 
FBS+supple
ments 
 
 
Buffy coats from healthy volunteer donors were obtained from the blood bank of the German 
Red Cross Society.  
 
2.1.9.2 Established cell lines 
The human MYCN-amplified NB cell lines (UKF-NB-2, UKF-NB-3 and UKF-NB-4) and the 
alveolar rhabdomyosarcoma cell lines (UKF-Rhb-1 and KFR) were established respectively 
from bone marrow metastases of patients with diagnosis of NB (stage IV disease) and 
alveolar rhabdomyosarcoma at the interdisciplinary laboratory for tumor and virus research, 
institute for medical virology, Johann Wolgang-Goethe University, Frankfurt, Germany [200-
205]. The alveolar rhabdomyosarcoma cell line HA-OH1 was a kind gift provided by Dr. E. 
Koscielniak (Olga Hospital, Stuttgart, Germany). The human rhabdomyosarcoma cell lines 
(RH-1 and RH-36-embryonal subtypes; RH-28, RH-30, and RH41-alveolar subtypes) were 
kindly provided by Dr. Peter J. Houghton (St. Jude’s Children’s Research Hospital, Memphis, 
TN, USA) [206-208]. The VCR-resistant UKF-NB-2 subline (designated UKF-NB-2
rVCR
10)     Materials and Methods 
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and araC-resistant H9 and Molt-4 cell sublines (designated H9
r100
ARAC and Molt-4
r100
ARAC 
respectively) were established by exposing parental cells to increasing concentrations of the 
drug [202]. The resistant sublines were grown for more than 6 months in IMDM 
supplemented with 10% FBS and containing 10 ng/ml VCR or 100 µM araC. Cells were 
subcultured at 5-day intervals. All experiments were performed using VCR- or araC-resistant 
cells subcultured at 5-day intervals without further addition of drug for up to 10 passages. 
 
2.2 Methods 
2.2.1 Cultivation of adherent eukaryotic cells 
RH-1, RH-28, RH-30, RH-36, RH-41, UKF-Rhb-1, KFR, HA-OH1, PC-3, LNCaP, DU145, 
UKF-NB4, UKF-NB-3, UKF-NB-2 and UKF-NB-2
rVCR
10 cell lines were propagated in 
IMDM supplemented with 10% FBS at 37°C in a humidified 5% CO2 incubator. The cells 
grew into confluent cell race and were subsequently passaged according to the following 
protocol: 
•  Old medium is discarded and the cells are washed 2x with sterile PBS. 
•  0.2 ml trypsin/EDTA is added to the cells to detach them from culture flask (50 ml, 
25cm
2). 
•  Cells are incubated at 37°C till they are completely detached (for about 5 min) from 
flask. 
•  Detached cells are re-suspended in 10 ml culture medium and distributed into new 
flasks containing medium according to splitting rate like 1:5, 1:10, 1:20. 
  
2.2.2 Cultivation of eukaryotic suspension cells 
Parental and araC-resistant H9 and Molt-4, C8166, P-815, HL-60 and Jurkat cell lines were 
cultured in IMDM containing 10% FBS at 37°C in a humidified CO2 incubator. For K562 cell     Materials and Methods 
  52
line, IMDM containing 20% FBS was used for cultivation. Cells were split every 5 days at a 
splitting rate of 1:10 (2 ml cell suspension + 18 ml culture medium) or 1:20.  
  
2.2.3 Polyclonal NK cell preparation 
PBMCs were isolated from the blood of healthy volunteers by Ficoll (Biocoll)-Hypaque 
centrifugation: Fifteen ml Ficoll was pipetted into a 50 ml falcon tube. Blood was diluted 
1.5x, i.e. 15 ml blood was mixed with 10 ml PBS + 2% FBS. The diluted blood was layered 
on Ficoll without mixing blood with Ficoll. The sample was centrifuged at 4°C for 30 min at 
400 g with no brake. After centrifugation, the upper plasma was removed and discarded 
without disturbing the plasma-Ficoll interface (Fig 2.1). The PBMCs layer at the plasma-
Ficoll interface was carefully removed and retained without disturbing 
erythrocyte/granulocyte pellet.  
 
 
 
Figure 2.1: Buffy coat separation by density centrifugation using Ficoll 
 
The PBMCs were washed once with PBS + 2% FBS. Freshly isolated PBMCs were 
transferred into IMDM + 10% human serum and incubated for 2 h at 37°C to allow adherence 
Serum 
Leucocyte ring (PBMCs) 
Ficoll 
Erythrocyte/Granulocyte     Materials and Methods 
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of monocytes to the bottom of the 75 cm
2 culture flasks. After incubation, the cell suspension 
was collected and NK cells were separated according to manufacturer’s protocol using the 
MACS NK cell isolation kit II (Miltenyi Biotec, Bergisch Gladbach, Germany). Separated 
NK cells were maintained in IMDM+10% FBS at 37°C in 5% humidified CO2 incubator. For 
experiments to determine the direct effect of VPA and SAHA on NK cell cytotoxicity, NK 
cells were stimulated with 100 U/ml IL-2 and simultaneously treated with VPA or SAHA for 
4 days. For other cytotoxic experiments, NK cells were stimulated with or without 100 U/ml 
IL-2 for 4 days.  
2.2.4 Cytotoxicity assay principle 
NK cells were tested for cytolytic activity against indicated target cells using the “aCella-
Tox” kit (Cell Technology, Mountain View, CA) that employs the coupled luminescent 
technology for the detection of cytotoxicity (Fig. 2.2) [209]. Target cells were plated in 
triplicate (5000 cells per well) in a 96 well white plate (Greiner Bio-One, Frickenhausen, 
Germany). Effector cells (NK cells) at indicated effector to target (E:T) ratios were added. 
Spontaneous effector- and target cell death was accomplished by including control wells of 
effector cells at numbers corresponding to those of their various E:T ratios and target cells 
according to the concentrations used for the assay. Twenty µl of lytic reagent (0.5% NP-
40/100 µl sample) was added to the target cells positive control (total glyceraldehyde-3-
phosphate dehydrogenase (G3PDH) release) 15 min to end of assay incubation. At the end of 
incubation, 100 µl of 2x enzyme assay reagent was added to each well. Fifty µl of 1x 
detection reagent was immediately added to each well. The plate was read at once in a 
luminometer (Glomax, Turner BioSystems, CA). For the mAb-mediated neutralization 
experiments, 10 µg/ml each of anti-PVR, anti-ULBP-2, and anti-ULBP-3 mAbs were used to 
block PVR, ULBP-2 and ULBP-3 expression on target cells. NKG2D was also blocked on 
NK cells with 10 µg/ml anti-NKG2D Ab. Isotype control IgG was used as negative control.     Materials and Methods 
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For redirected killing experiments, 1 µg/ml of purified NKp30 and NKp46 mAbs was used to 
block NKp30 and NKp46 receptors on NK cells. IMDM supplemented with 1% heat 
inactivated FBS was used as assay medium. The percent cytotoxicity was calculated as 
follows: [(experimental G3PDH release - spontaneous G3PDH release from effector cells 
alone - spontaneous G3PDH release from target cells alone)/(maximum G3PDH release from 
target cells - spontaneous G3PDH release from target cells)]x100. The spontaneous target cell 
release was always < 20% of maximum release. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: assay principle of the coupled luminescent method (adapted from reference 209) 
 
2.2.4.1 Redirected lysis 
Redirected lysis is an antibody-mediated lysis of Fc receptor bearing target cells. It is an assay 
used to determine the specific function of a receptor expressed by cytotoxic cells. To asses the 
direct effect of VPA and SAHA on the activity of NK cell triggering recptors, NK cells were 
first cultured for 4 day in IL-2 with or without VPA or SAHA. Five thousand effector cells 
(both HDACi-treated and control NK cells) were plated in triplicate in a 96 well white plate.     Materials and Methods 
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Purified NKp30 and NKp46 mAbs (1 µg/ml) were then used to block NKp30 and NKp46 
receptors on effector cells for 30 mins before addition of 5000 target cells. The FcγR
+ P815 
cell line was used as target cell line. A 4 h cytotoxicity experiment was performed as 
described above in section 2.2.4. 
 
2.2.5 The flow cytometric principle 
Flow cytometry uses the principles of light scattering, light excitation, and emission of 
fluorochrome molecules to generate specific multi-parameter data from particles and cells in 
the size range of 0.5 µm to 40 µm diameter. It is used for the quantification of antigens that 
are expressed on the cell membrane as well as intracellular antigens. Cells are hydro-
dynamically focused in a sheath of PBS before intercepting an optimally focused light source. 
Lasers (argon laser in the case of FACScan) are most often used as a light source in flow 
cytometry. As cells or particles of interest intercept the light source they scatter and 
fluorochromes are excited to a higher energy state. As the molecules relax to a lower state, 
energy is released as a photon of light with specific spectral properties unique to different 
fluorochromes (Table 2.1) [210].      Materials and Methods 
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Table 2.1: Fluorescence spectra of commonly used fluorochromes. The bottom part of the table summarizes the 
emission wavelengths of various light sources used in flow cytometry. The 488 nm line of the argon ion laser is 
extended over the spectra. (adapted from reference 210, p245). 
Photo multiplier tubes (PMT's) are detectors which collect the photon emissions from each 
"event" and convert them to analog voltages. The electrical pulses originating from light 
detected by the PMTs are then processed by a series of linear and log amplifiers. Logarithmic     Materials and Methods 
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amplification is most often used to measure fluorescence in cells. This type of amplification 
expands the scale for weak signals and compresses the scale for strong or specific 
fluorescence signals. After the different signals or pulses are amplified they are processed by 
an Analog to Digital Converters (ADC's) and recorded as data files (one parameter, two 
parameter histograms). Optical filters are placed before the detectors so that only wavelengths 
of light corresponding to specific fluorochrome emissions are collected by each detector (e.g. 
FITC emits in the green region therefore a 30 nm bandpass filter centered at 525 nm could be 
used to collect light from this fluorochrome). Light scattered at the same wavelength and 
direction as the laser light, primarily from the surface of the cell, correlates with relative cell 
size (Forward Angle Light Scatter (FSC)) while light scattered 90 degrees to the laser (Side 
Scatter (SSC)) usually from internal structures, correlates with granularity. By correlating 
these two parameters, one can discriminate subpopulations of cells in peripheral blood 
samples, for example. Signals corresponding to cell debris or cell aggregates can also be 
detected and excluded from analysis on the basis of forward and side scatter. One unique 
feature of flow cytometry is that it measures fluorescence per cell or particle. This contrasts 
with spectrophotometry in which the percent absorption and transmission of specific 
wavelengths of light is measured for a bulk volume of sample. 
Staining cells with multiple fluorochromes conjugated to antibodies or fluorochromes directed 
at other specific targets such as DNA, cytokines, or other proteins distinguishes cell 
subpopulations which can be quantified. Data is displayed and analyzed using histograms or 
two-dimensional dot plots on a computer system. 
Histogram Files: Histogram files can be in the form of one-parameter or two-parameter files 
and consist of a list of events for a 1 parameter or 2 parameter histogram.     Materials and Methods 
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One-Parameter Histograms: A one parameter histogram is a graph of cell count on the y-axis 
and the measurement parameter on x-axis. All one-parameter histograms have 1,024 channels.  
These channels correspond to the original voltage generated by a specific light event detected 
by the PMT detector. In other words, the ADC assigns a channel number based on the pulse 
height for individual events. Therefore, brighter specific fluorescence events will yield a 
higher pulse height and thus a higher channel number when displayed as a histogram. 
 
Figure 2.3: one-parameter histogram 
Two-Parameter Histograms: A graph representing two measurement parameters, on the x- and 
y-axes, and cell count height on a density gradient. This is similar to a topographical map. 
One can select 64 or 256 channels on each axis of two-parameter histograms. Particle counts 
are shown by dot density or contour plots. 
 
Figure 2.4: two-parameter histogram dot plot displaying FL1-FITC on the x-axis and FL2-PE on the y-axis.     Materials and Methods 
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2.2.5.1 Determination of cell cycle using propidium iodide 
The cell cycle of a proliferating cell is made up of 4 phases. These phases are characterized by 
changes in the DNA-content of the cell. The G0/G1-phase (Gap 1) marks the time period after 
a mitotic division. During this phase, the DNA-content within the cell is diploid (2n). 
Depending on cell type, the cell may now differentiate or continue to proliferate. Proliferating 
cells enter into the DNA-synthesis phase (S-phase). At the end of the S-phase, the cells now 
have a double diploid DNA-content (4n).  In the following G2-phase, the DNA-content 
remains unchanged and the cell synthesizes mitotic active enzymes. Post-replicative repairs 
may also occur during the G2-phase. Mitosis (M) follows subsequently and the cell divides 
into two diploid daughter cells which then enter into the G0/G1-phase.  
DNA can be stained with DNA-intercalating fluorochrome propidium iodide (PI). Through 
this means and with the aid of a flow cytometer, the DNA-content as well as the cell cycle 
profile of a cell population can then be ascertained and graphically represented on a histogram 
[211].  
 
Figure 2.5: Cell cycle distribution- histogram showing sub G1 fraction 
 
The DNA-content of apoptotic cells (sub G1) is less than 2n. This hypodiploidity results from 
DNA fragmentation during the course of apoptosis and necrosis. However in order to be seen     Materials and Methods 
  60
in the sub G1 area, a cell must have lost enough DNA to appear there; so if cells enter 
apoptosis from the S- or G2/M-phase of the cell cycle, they may not appear in the sub G1 
peak. To detect early apoptotic cells, the cells are first fixed with 70% ethanol. This will 
permeabilize the membrane, allowing small molecular DNA fragments to be extracted from 
the cell. 
 
2.2.5.2 Effect of HDACi on NK cell viability 
PI staining was used to determine the apoptotic rate in IL-2-activated NK cells upon treatment 
with HDACi, SAHA and VPA. After 4 days HDACi treatment (1x10
6 cells were seeded in a 
12 well plate), 2 ml cell suspension was filled into the FACS tubes and centrifuged (5 min, 
400 g, 4°C). The supernatant was discarded while the cell pellet was washed with 2 ml PBS 
and centrifuged. The cells were fixed in 2 ml 70% ethanol for at least 2 h or overnight at -
20°C. After fixation, cells were centrifuged, supernatant discarded and cells were washed 
once with PBS and centrifuged again. The cell pellet was then resuspended in 500 µl PI 
working solution (100 µl 0.1% Triton X-100 + 200 µl 1 mg/ml PI Stock solution + 9.7 ml 
PBS). The samples were incubated in the dark for 30 min at room temperature. Afterwards, 
the cell cycle profile was determined using flow cytometer in FL2-channel (separated in FL2-
A and FL2-W, doublet discrimination module). Ten thousand cells were measured from each 
sample. Untreated IL-2-activated NK cells were used as control. Becton Dickinson 
FACSCalibur was used for all measurements. Results were evaluated using CellQuest Pro 
programme.  
 
2.2.5.3 Measurement of cell surface receptors 
For quantitative analysis of the expression of cell surface and intracellular receptors, a one 
color cytofluorometric analysis was carried out. Cells were stained with appropriate mAb as 
follows:     Materials and Methods 
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•  Cells were harvested (adherent cells were first trypsinized while suspension cells were 
distributed directly into polystyrene round bottom 12x75 mm Falcon tubes), washed 
twice and cell suspension was then adjusted to a concentration of 1x10
6 cells/ml in 
FACS buffer.  
•  Cells were stained with 10-20 µg/ml appropriate mAb according to manufacturer’s 
protocol.  
•  After incubation, cells were washed twice by centrifugation at 400 g for 5 min and 
resuspended in 100 µl FACS buffer.  
•  20 µl of fluorochrome-labeled secondary Ab were added. 
•  Cells were incubated at room temperature for at least 20 min in the dark.  
•  Cells were washed twice, resuspended in 500 µl FACS buffer and analyzed by flow 
cytometry. 
•  In case of conjugated mAbs, the secondary Ab step was left out. 
•  For detection of intracellular antigens (perforin, granzyme B, IFN-β, IFN-γ) cell 
fixation and permeabilization steps were done prior to staining with mAbs. For this 
purpose, cells were fixed with 200 µl Cytofix/Cytoperm for 20 min at room 
temperature, washed and then permeabilized with 200 µl PermWash for 20 min at 
room temperature. 
 
2.2.6 Principle of RT-PCR 
RT-PCR is a laboratory technique for amplifying a defined piece of a ribonucleic acid (RNA) 
molecule. The RNA strand is first reverse transcribed into its DNA complement or 
complementary DNA (cDNA), followed by amplification of the resulting DNA using PCR. 
This can either be a 1 or 2 step process. PCR itself is the process used to amplify specific 
parts of a DNA molecule, via the temperature-mediated enzyme DNA polymerase. In the first 
step of RT-PCR, called the "first strand reaction," cDNA is made from a messenger RNA     Materials and Methods 
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template using dNTPs and an RNA-dependent DNA polymerase (reverse transcriptase) 
through the process of reverse transcription. RT-PCR exploits a characteristic of mature 
mRNAs known as the 3' polyadenylated region, commonly called the poly(A) tail, as a 
common binding site for poly(T) DNA primers. In the case of bacterial mRNA, which lack a 
poly(A) tail sequence-specific primers can be generated to amplify the target mRNA 
sequence. These primers will anneal to the 3' end of every mRNA in the solution, allowing 5'-
>3' synthesis of cDNA by the reverse transcriptase enzyme. cDNA can also be prepared from 
mRNA by using gene specific primer or random hexamer primers. 
After the reverse transcriptase reaction is complete, and cDNA has been generated from the 
original single-stranded mRNA, standard PCR, termed the "second strand reaction," is 
initiated. If the initial mRNA templates were derived from the same tissue, subsequent PCR 
reactions can be used to probe the cDNA library that was created by reverse transcription. 
Primers can be designed to amplify target genes being expressed in the source tissue. 
Quantitative real-time PCR can then be used to compare levels of gene expression. 
1.  A thermostable DNA polymerase and the upstream and downstream DNA primers are 
added. 
2.  The reaction is heated to temperatures above 37°C to facilitate sequence specific 
binding of DNA primers to the cDNA. 
3.  Further heating allow the thermostable DNA polymerase to make double-stranded 
DNA from the primer bound cDNA. 
4.  The reaction is heated to approximately 95°C to separate the two DNA strands. 
5.  The reaction is cooled enabling the primers to bind again and the cycle repeats. 
After approximately 30 cycles, millions of copies of the sequence of interest are generated. 
The original RNA template is degraded by RNase H, leaving pure cDNA (plus spare primers).     Materials and Methods 
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The exponential amplification via RT-PCR provides for a highly sensitive technique, where a 
very low copy number of RNA molecules can be detected. RT-PCR is widely used in the 
diagnosis of genetic diseases and, quantitatively, in the determination of the abundance of 
specific different RNA molecules within a cell or tissue as a measure of gene expression. 
 
2.2.7 Real-time RT-PCR (SYBR Green Principle) 
SYBR Green provides the simplest and most economical format for detecting and quantitating 
PCR products in real-time reactions. SYBR Green binds double-stranded DNA, and upon 
excitation emits light. Thus, as a PCR product accumulates, fluorescence increases. The 
advantages of SYBR Green are that it is inexpensive, easy to use, and sensitive. The 
disadvantage is that SYBR Green will bind to any double-stranded DNA in the reaction, 
including primer-dimers and other non-specific reaction products, which results in an 
overestimation of the target concentration. For single PCR product reactions with well 
designed primers, SYBR Green can work extremely well, with spurious non-specific 
background only showing up in very late cycles. Since the dye binds to double-stranded 
DNA, there is no need to design a probe for any particular target being analyzed.  
 
2.2.7.1 Real-time RT-PCR 
Total RNA was extracted from IL-2-activated NK cells either untreated or treated with 0.5 
mM VPA or 0.5 µM SAHA and parental as well as araC-resistant H9 and Molt-4 cell lines 
using TRI reagent (Sigma-Aldrich, St. Louis, USA) according to the manufacturer’s protocol. 
The TRI reagent allows the simultaneous isolation of RNA, DNA and proteins. The reagent 
contains in addition to phenol, guanidine isothiocyanate solution which lyses the cells, 
denatures and inactivates the proteins. The DNA fragments later dissolve in the phenol [212, 
213]. Reverse transcription was carried out with reagents from Applied Biosystems (Foster     Materials and Methods 
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City, USA) according to the manufacturer’s instructions. Relative quantification of gene 
expression was performed with the ABI PRISM 7900HT in real-time RT-PCR using SYBR 
Green reagents (Applied Biosystems, Darmstadt, Germany) according to a standard thermal 
profile: denaturation at 95°C for 15 seconds, annealing/extension at 60°C for 60 seconds with 
40 repeats. The β-actin housekeeping gene was used to internally standardize the levels of 
gene expression. Primers used are as indicated in section 2.1.5.2 of materials and methods. All 
the samples were performed at least in duplicates. Threshold levels and baseline were 
optimized. Relative quantification was determined with the SDS2.1 software (Applied 
Biosystems) provided with the ABI PRISM 7900HT (ΔΔCt method). Relative expression of 
each transcript was obtained by calculating the ΔCT as the difference between the PCR CT of 
the analyzed gene (NKp46, NKp30, ULBP-2 or ULBP-3) and β-actin used as reference. The 
difference in expression levels between untreated and treated NK cells was calculated by 
comparing the ΔCT of untreated NK cells (used as control) to that of samples from VPA or 
SAHA treated NK cells. The difference in expression levels between parental cell culture and 
araC-resistant cell cultures was calculated by comparing the ΔCT of parental H9 and Molt-4 
cells (used as control) to that of araC-resistant H9 and Molt-4 cells. The results are presented 
as fold decrease/increase. 
 
2.2.8 NK receptors cross-linking and perforin/granzyme B granule release 
NK cells were stimulated by mAb cross-linking as previously described [214]. After 4 days of 
culture in IL-2 with or without VPA or SAHA, cells were labeled with 1 µg/ml appropriate 
mAbs (NKp30, NKp46) for 30 mins at 4°C. After washing, cells were stimulated with 10 
µg/ml AffiniPure F(ab’)2 Fragment Goat Anti-Mouse IgG (Jackson ImmunoResearch, West 
Grove, USA) for 5 min at 37°C. The reaction was stopped with ice-cold PBS. After overnight 
incubation at 37°C, supernatants were collected for analysis and quantification of granule     Materials and Methods 
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release by ELISA assay (Perforin/Granzyme B-ELISA kit, Diaclone Research, Besancon 
Cedex, France) according to manufacturer’s instructions. 
 
2.2.9 Measurement of IFN-γ production 
Purified NK cells were treated with 100 U/ml IL-2, and either 0.5 µM SAHA or 0.5 mM VPA 
were added simultaneously for 72 h. NK cells treated with 100 U/ml IL-2 only were used as 
control. Supernatants were collected and tested for production of IFN-γ. The amounts of IFN-
γ were determined using the Quantikine Human IFN-γ ELISA kit (R&D Systems, Wiesbaden, 
Germany) according to manufacturer’s protocol. 
 
2.3.0 Measurement of NFκB activation 
NFκB p50 and NFκB p65 activation were determined using the TransAM
TM NFκB Chemi kit 
(Active Motif, Carlsbad, USA). Purified NK cells were treated with 100 U/ml IL-2, and either 
0.5 µM SAHA, 0.5 mM VPA, or 1 µM BAY 11-7085 were added simultaneously for 4 days. 
NK cells treated with 100 U/ml IL-2 only were used as control. Nuclear extracts were then 
prepared using the nuclear extract kit (Active Motif, Carlsbad, USA). The extracts were used 
for the NFκB activation assay according to the manufacturer’s protocols. A mutated 
consensus oligonucleotide (should have no effect on NFκB binding) as well as a wild-type 
consensus oligonucleotide (a competitor for NFκB binding) was used to monitor the 
specificity of the assay. Twenty pmol/well of each oligonucleotide was used for the assay. 
 
2.3.1 MTT assay 
MTT assay is a laboratory test and a standard colorimetric assay (an assay which measures 
changes in color) for measuring cellular proliferation (cell growth). It can also be used to 
determine cytotoxicity of potential medicinal agents and other toxic materials.     Materials and Methods 
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Yellow MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a tetrazole) is 
reduced to purple formazan in the mitochondria of living cells. A solubilization solution 
(usually either dimethyl sulfoxide (DMSO), an acidified ethanol solution, or a solution of the 
detergent sodium dodecyl sulfate (SDS) in dilute hydrochloric acid) is added to dissolve the 
insoluble purple formazan product into a colored solution. The absorbance of this colored 
solution can be quantified by measuring at a certain wavelength by a spectrophotometer. The 
absorption maximum is dependent on the solvent employed. 
 
Figure 2.6: MTT reductase scheme 
This reduction takes place only when mitochondrial reductase enzymes are active, and 
therefore conversion can be directly related to the number of viable (living) cells. When the 
amount of purple formazan produced by cells treated with an agent is compared with the 
amount of formazan produced by untreated control cells, the effectiveness of the agent in 
causing death of cells can be deduced, through the production of a dose-response curve.  
2.3.1.1 Cytotoxicity of araC on leukemic cell lines 
Cell viability of parental and araC-resistant H9 and Molt-4 cells upon araC treatment was 
investigated using MTT assay. The cells were grown in 96-well plates with and without 
Formazan (purple)  MTT (yellow)     Materials and Methods 
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addition of drug. After the incubation period, MTT reagent was added for 4 h. Thereafter, 100 
μl of SDS solution (20% SDS in a 1:1 Dimethylformamide (DMF)/H2O solution) was added 
for further 4 h. Plates were read on a multi-well scanning spectrophotometer (Tecan, 
Crailsheim, Germany) at a wavelength of 620 nm and a reference wavelength of 690 nm. Cell 
viability was determined as the relative reduction of the amount of MTT reduced by cells to 
its purple formazan derivative, which correlates with the amount of viable cells in relation to 
cell control. The concentration inhibiting 50% of cell growth (IC50) was calculated by 
producing a dose-response curve.  
2.3.2 Western Blot Principle 
A western blot (alternately, immunoblot) is a method to detect a specific protein in a given 
sample of tissue homogenate or extract. It uses gel electrophoresis to separate native or 
denatured proteins by the length of the polypeptide (denaturing conditions) or by the 3-D 
structure of the protein (native/ non-denaturing conditions). The proteins are then transferred 
to a membrane (typically nitrocellulose or PVDF), where they are probed (detected) using 
antibodies specific to the target protein. The most common type of gel electrophoresis 
employs polyacrylamide gels and buffers loaded with SDS. SDS-PAGE (SDS polyacrylamide 
gel electrophoresis) maintains polypeptides in a denatured state once they have been treated 
with strong reducing agents to remove secondary and tertiary structure (e.g. S-S disulfide 
bonds to SH and SH) and thus allows separation of proteins by their molecular weight. 
Sampled proteins become covered in the negatively charged SDS and move to the positively 
charged electrode through the acrylamide mesh of the gel. Smaller proteins migrate faster 
through this mesh and the proteins are thus separated according to size (usually measured in 
kilo Daltons, kD). The concentration of acrylamide determines the resolution of the gel - the 
greater the acrylamide concentration the better the resolution of higher molecular weight 
proteins. Proteins travel only in one dimension along the gel for most blots.     Materials and Methods 
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Samples are loaded into wells in the gel. One lane is usually reserved for a marker or ladder, a 
commercially available mixture of proteins having defined molecular weights, typically 
stained so as to form visible, colored bands. When voltage is applied along the gel, proteins 
migrate into it at different speeds. These different rates of advancement (different 
electrophoretic mobilities) separate into bands within each lane. 
It is also possible to use a two-dimensional (2-D) gel which spreads the proteins from a single 
sample out in two dimensions. Proteins are separated according to isoelectric point (pH at 
which they have neutral net charge) in the first dimension, and according to their molecular 
weight in the second dimension. 
2.3.2.1 Western Blot analyses of leukemic cells 
Parental and araC-resistant H9 and Molt-4 cell lines were washed with ice cold PBS, after 
which 1 ml freshly prepared Triton X-100 lysis buffer containing 1% orthovanadate, 1% 
okadaic acid, 1.2% protease inhibitor mix (PIM) and 0.4% PMSF was added. Cells were 
incubated on ice for 10 min and centrifuged for 7 min at 7500 g. Supernatants containing the 
cell lysates were collected. Protein concentration of the cell lysates was determined according 
to BioRad protocols. The same concentration of protein from all samples was diluted 1:1 with 
Laemmli buffer (950 µl Laemmli + 50 µl β-Mercaptoethanol) and heated for 5 min at 95°C. 
Samples were stored at -80°C when not used immediately. Samples were subjected to SDS-
PAGE (using 10% acrylamide gels) before transfer to nitrocellulose membranes (Schleicher 
& Schuell, Dassel, Germany) using the Mini-Protean II system (Bio-Rad, Munich, Germany) 
according to manufacturer’s protocols. After transfer, blots were blocked in blocking buffer 
containing 3% BSA for 1 h at room temperature to saturate the non-specific protein-binding 
sites on the nitrocellulose membrane. The following primary antibodies were used: 
extracellular signal-regulated kinase (ERK), anti-phospho-ERK1/2, AKT, anti-phospho-AKT     Materials and Methods 
  69
(ser 473) (Cell Signaling, Beverly, USA). The blot was incubated overnight with the primary 
antibody diluted in TBS at 4°C with gentle agitation. Following a 1 h incubation period with 
peroxidase-conjugated secondary antibody at room temperature visualization was performed 
by enhanced chemiluminescence (ECL) using a commercially available kit (Amersham, 
Liverpool, UK).   
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3.0 Results 
3.1 Purity of separated NK cells 
NK cells are primarily characterized as CD56 positive and CD3 negative cells. After NK cell 
separation from PBMCs, the purity of separated NK cells was determined using flow 
cytometry. The results show 98% of separated cells to be CD56+CD3- (Fig. 3.1). 
 
Figure 3.1: Dot- and histogram plots of PBMCs before and after separation with MACS NK cell isolation kit II. 
Cells were stained with APC-conjugated CD3 and PE-conjugated CD56 mAbs. About 98% of separated cells 
were CD56+CD3- 
 
3.2 Establishing the coupled luminescent method (CLM) for measuring NK cytotoxicity 
We first determined the linear response of “aCella-Tox” within K562 and NB cell lines. This 
was accomplished by titrating all target cells in the cytotoxicity assay medium from 30,000 to 
250 cells/well. Twenty µl of the lytic agent, NP-40, was added to each well. Lysed cells were 
further incubated for the length of the assay (4 h) before adding the enzyme assay reagent and 
detection reagent as described in materials and methods. The luminescence was then 
measured in a luminometer. Up to 20,000 cells/well were within the linear range of the assay 
(Fig 3.2a). The assay was then standardized using NK sensitive K562 cell line as target and    
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IL-2-activated NK cell as effector cell. Different E:T ratios, and different incubation times 
were used. As shown in Fig. 3.2b, K562 target cells were lysed at E:T ratio as low as 0.5:1 
(9% ± 2.4% lysis after 2 h). Optimal lysis of target cells was achieved after 4 h of 
coincubation with IL-2-activated NK cells at an E:T ratio of 4:1 (75% ± 3.13% lysis).  
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Figure 3.2: [a] Linear response of “aCella-Tox” within K562 and NB cell lines. The relative luminescent unit 
(RLU) of cells treated with lytic agent for 4 h is shown [b] Cytotoxicity of IL-2-activated NK cells against K562 
assessed by G3PDH release. Five thousand K562 target cells were coincubated with IL-2 activated NK cells at 
the indicated E:T ratios for 2 h and 4 h at 37°C. The results are mean ± standard deviation (SD) of 3 independent 
experiments.  
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3.3 Validating CLM using NB as target cells 
CLM needs to be validated in order for it to be used as a standard method for measuring 
cytotoxicity. For this purpose, the applicability of CLM was tested by measuring the cytolytic 
activity of IL-2-activated NK cells against solid tumors (NB cell lines UKF-NB-2, UKF-NB-3 
and UKF-NB-4), and  chemoresistant NB cell line (UKF-NB-2
rVCR
10). The results presented 
in Fig. 3.3 reveal that target cells were lysed in an E:T cell ratio dependent manner. 
Chemoresistant target cells were generally more sensitive to IL-2-activated NK cell lysis than 
their respective parental counterparts (45% ± 1% vs. 19% ± 3% respectively for UKF-NB-
2
rVCR
10 and UKF-NB-2 at E:T ratio of 4:1).  
 
Figure 3.3: IL-2-activated NK cell-mediated cytotoxicity against NB. Killing of parental NB cell lines and 
VCR-resistant NB cell line was assessed by G3PDH release. Five thousand target cells were coincubated with 
IL-2-activated NK cells at the indicated E:T ratios for 4 h at 37°C.  The results are mean ± SD of 3 independent 
experiments. 
 
Recently, it was shown that the susceptibility of a subset of NB cells to NK cell-mediated 
lysis was dependent on the expression level of PVR specifically recognized by DNAM-1 
[215-218]. To verify the role of PVR expression in the susceptibility of NB to NK cell lysis, 
the surface expression of PVR on UKF-NB-2, UKF-NB-3, UKF-NB-4 and UKF-NB-2
rVCR
10 
as well as its role in NK cell lysis of NB cell lines were analyzed. PVR was markedly 
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expressed in all cell lines tested (Fig. 3.4a). Contrasting these results, the expression of other 
NK activating receptor (NKG2D) ligands like MICA/B were not found on the surface of NB 
cells. The differential expression of PVR on NB cells seems to correlate with NK sensitivity. 
Blocking PVR with mAb inhibited NK cell lysis of NB cells (Fig. 3.4b), indicating that NK 
cell cytotoxicity of NB cells is dependent on the level of PVR expressed on tumor cells. 
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Figure 3.4: Role of PVR in NK cell-mediated cytotoxicity against NB cells. [a] Flow cytometric analysis for the 
expression of PVR in NB cells. Columns indicate relative expression of one representative of at least five 
separate experimens. [b] Five thousand NB cells were coincubated with IL-2-activated NK cells at the indicated 
E:T ratio for 4 h at 37°C either in  the absence or presence of 10 µg/ml anti PVR mAb. IgG isotype control was 
used as negative control. The results are mean ± SD of 3 independent experiments.   
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3.4 Validating CLM using other cell types as target 
CLM was further tested on several other target cell types including rhabdomyosarcoma cell 
lines (RH-1, RH-28, RH-30, RH-36, RH-41, UKF-Rhb-1, HA-OH1, and KFR), prostate 
cancer cell lines (LNCaP, DU145, and PC-3), and the human T-cell leukemia cell lines 
(C8166, H9, and Molt-4). IL-2-activated NK cells were used as effector cells. 
Rhabdomyosarcoma cell lines were generally resistant to NK cell lysis except for RH-28 and 
RH-30. The androgen-dependent LNCaP cell line was most sensitive to NK cell lysis while 
the androgen-independent DU145 and PC-3 cell lines were resistant to NK cell lysis. Of the 3 
leukemic cell lines, only H9 and Molt-4 cell lines were sensitive to NK cell lysis (Fig. 3.5).  
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Figure 3.5: IL-2-activated NK cell-mediated cytotoxicity against different cell types. Killing of indicated cell 
lines was assessed by G3PDH release. Five thousand target cells were coincubated with IL-2-activated NK cells 
at the indicated E:T ratios for 4 h at 37°C.  The results are mean ± SD of 3 independent experiments. 
 
CLM proved to be a highly sensitive method to measure NK cytolytic activity as NK cell lysis 
can be achieved even at low E:T ratios. The effects of HDACi on NK cell cytolytic activity 
and the sensitivity of parental and araC-resistant leukemic cell lines to NK cell lysis were thus 
investigated using CLM. 
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3.5 Effect of HDACi on viability of NK cells 
The effect of HDACi at clinically relevant concentrations [219, 126] (0.25 to 1 mM and 0.5 to 
2 µM for VPA and SAHA respectively) on viability of NK cells was first studied. For this 
purpose, NK cells were cultured simultaneously for 4 days with IL-2 and SAHA or VPA. 
Dead cells were identified by fractional DNA content (“sub G1 fraction”). NK cells treated 
with IL-2 alone were used as control. Results revealed SAHA to be clearly toxic to NK cells 
in the range of therapeutic concentrations [126]. About 48% of NK cells were found in the 
sub G1-phase (indicating induction of cell death) upon exposure to 2 µM SAHA compared to 
9% in control cells (Fig. 3.6). In contrast, 0.5 µM SAHA treatment resulted in no or at most 
minimal NK cell death, while ≤ 0.5 mM VPA was only slightly toxic to NK cells (1.6% cell 
death induction when compared to control). Both VPA and SAHA also blocked cell cycle 
progression into the S- and G2/M-phase in a dose dependent manner (Fig. 3.6). Based on 
these results, 0.5 mM VPA and 0.5 µM SAHA were selected to investigate the influence of 
non-toxic HDACi concentrations on NK cell activity.     
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Figure 3.6: Viabilty and proliferation of NK cells after exposure to HDACi. Primary NK cells from healthy 
donors were treated simultaneously with 100 U/ml IL-2 and either VPA or SAHA at indicated concentrations for 
4 days. The effect of HDACi on cell cycle was determined by staining cells with PI. M1, M2, M3 and M4 
indicate sub G1-, G0/G1-, S- and G2/M-phases respectively; empty histograms represent VPA treated cells; grey 
histograms represent SAHA treated cells; black histogram represents untreated (control) NK cells; numbers in 
parentheses indicate respective concentrations of HDACi used; values represent percentage of cells in the 
different phases. The percentages of cells in G0/G1, S and G2/M phases were deduced from the number of 
viable cells (set to 100%) after subtracting the dead cells (sub G1) from total gated cells. One representative of 3 
different experiments is shown. 
 
3.6 HDACi suppress IL-2-mediated NK cell cytotoxicity  
The role of HDACi on NK cell cytotoxicity was next investigated. IL-2-activated NK cells 
were treated with either SAHA or VPA for 4 days after which the cytotoxicity against K562 
cells was determined using a 4 h CLM assay. Interestingly, both SAHA and VPA 
dramatically suppressed IL-2-activated NK cell cytotoxicity in an E:T cell ratio-dependent    
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manner (Fig. 3.7a). Decreased NK lytic activity of HDACi treated NK cells was also observed 
in other leukemic cell lines including Jurkat T cells and HL-60 cells (Fig. 3.7b). A 24 h 
pretreatment of Jurkat T cells and HL-60 cells with SAHA resulted in almost 60% (54% vs. 
86%) and 14% (57% vs. 65%) increased NK cell-mediated lysis in SAHA treated Jurkat and 
HL-60 cells respectively. The increased NK cell lysis was however suppressed when SAHA 
treated NK cells were used as effector cells (Fig. 3.7b). Taken together, Jurkat T cells and 
HL-60 cells become more susceptible to NK cell-mediated lysis upon exposure to SAHA 
while NK cell activity gets repressed upon treatment with SAHA. In contrast, treatment of 
K562 for 24 h with 1 µM SAHA decreased its susceptibility to NK cell lysis by 50% [Fig. 
3.7b]. 
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Figure 3.7: HDACi suppress NK cell cytotoxicity. Primary NK cells from healthy donors were treated 
simultaneously with 100 U/ml IL-2 and either 0.5 mM VPA or 0.5 µM SAHA for 4 days. Primary NK cells 
treated only with 100 U/ml IL-2 were used as control. [a] A 4 h NK cell cytotoxicity assay against K562 target 
cells was performed at indicated E:T ratios. Columns represent means of triplicate of one representative 
experiment; error bars indicate ± SD. [b] A 4 h NK cell cytotoxicity assay against K562, Jurkat T cells and HL-
60 cells, pretreated with 1 µM SAHA for 24 h at an E:T ratio of 2:1 was carried out. [-] indicate without SAHA 
[+] indicate with SAHA. Columns represent means of triplicate of one representative experiment; error bars 
indicate ± SD.  
 
3.7 HDACi down-modulate NK cell activating receptors expression 
NK cell cytotoxicity is a complex process that requires adhesion to target cells, synapse 
formation and signal transduction leading to granule polarization and exocytosis. 
Accordingly, it is conceivable that HDACi might interfere with different steps in the process. 
To address these issues, the surface expression patterns of NKp30, NKp44, NKp46, NKG2D 
and DNAM-1, NKG2A and KIR in untreated as well as in SAHA and VPA treated NK cells 
were investigated. A correlation between NK cell cytotoxicity and NK cell receptor 
expression pattern was observed. The lytic capacity of NK cells treated with HDACi was 
associated with a high decreased surface expression of NKp30 and NKp46 while NKp44, 
NKG2D and DNAM-1 were not significantly changed. No changes were observed in the 
surface expression of KIR and NKG2A inhibitory receptors (Fig. 3.8a). To show whether the 
expressions of NKp46 and NKp30 are also influenced at the transcriptional level upon 
HDACi treatment, we examined the gene expression patterns of NKp46 and NKp30 in 
untreated and HDACi treated NK cells. Real-time RT-PCR results revealed a 5- and 9-fold 
decrease as well as a 9- and 12-fold decrease expression in NKp46 and NKp30 respectively 
for VPA and SAHA treated NK cells when compared to untreated NK cells (Fig. 3.8b).  
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Figure 3.8: HDACi down-modulate expression of NK cell activating receptors. Primary NK cells from healthy 
donors were treated simultaneously with 100 U/ml IL-2 and either 0.5 mM VPA or 0.5 µM SAHA for 4 days. 
Primary NK cells treated only with 100 U/ml IL-2 were used as control. [a] Flow cytometric analysis for the 
expression of indicated NK cell activating or inhibitory receptors. Columns indicate relative expression of one 
representative of at least five separate experiments. [b] Real-time RT-PCR for the mRNA expression levels of 
the different transcripts. Data are expressed as fold decrease of mRNA expression in VPA or SAHA treated NK 
cells relative to untreated (control) NK cells. Histograms are representative of results obtained with NK cells 
derived from 3 different donors. Each experiment was run in duplicate; error bars indicate ± SD. 
 
HDACi suppressed NK cell activity and NCR surface expression only when added 
simultaneously with IL-2, while they did not influence NK cells cultured without IL-2 (Fig. 
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3.9). Basically NK cell activating/inhibitory receptor expression levels were 3- to 4-fold 
higher in IL-2 cultured NK cells than in NK cells cultured without IL-2.  
 
Figure 3.9: HDACi does not suppress cytotoxicity of NK cells not treated with IL-2. Primary NK cells from 
healthy donors were treated with either 0.5 mM VPA or 0.5 µM SAHA for 4 days. Primary NK cells treated 
without IL-2 were used as control. A 4 h NK cell cytotoxicity assay against K562 target cells was performed at 
indicated E:T ratios. Columns represent means of triplicate of one representative experiment; error bars indicate 
± SD. 
 
Since NK cell cytolysis also depends on binding mediated by adhesion molecules like LFA-1, 
effects of HDACi on LFA-1 surface expression were determined. It was also determined 
whether HDACi influence IL-2 receptor since only NK cells cultured with IL-2 showed 
impaired activity upon HDACi treatment. HDACi did not significantly modify the expression 
neither of LFA-1 nor of IL-2 receptors (CD25, CD122 and CD132) on NK cells (Table 3.1). 
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Table 3.1: Flow cytometric analysis for the expression of indicated receptors 
 relative  expression
a    
Receptors  NK+IL-2  NK + IL-2 + 0.5 mM 
VPA 
NK + IL-2 + 0.5 µM 
SAHA 
LFA-1  20 ± 2  23 ± 3  19 ± 2.5 
CD25  37 ± 3.3  34 ± 4  40 ± 1 
CD122  15 ± 4  17 ± 2  14 ± 3 
CD132  26 ± 2.5  22 ± 4.5  28 ± 2 
a Results are expressed as relative fluorescent unit ± SD of triplicates of one representative experiment.  
 
These results suggest that HDACi act directly on selected NK cell receptors rather than by 
interfering with the ability of NK cells to respond to IL-2 or NK cell binding to target cells. 
 
3.8 HDACi suppress NK cell function 
To assess whether HDACi-induced modulation of NKp46 and NKp30 receptors resulted in an 
alteration of NK cell activity, treated and untreated NK cells were compared in a redirected 
killing assay against FcγR
+ P815 target cell line. The FcγR
+ P815 cell line has been 
extensively used for mAb-mediated redirected killing assays using NK cells and mAbs 
capable of triggering their cytolytic functions [220-222]. This would allow the assessment in a 
cytolytic assay the direct effect of VPA and SAHA on the specific activity of the trigerring 
receptors NKp46 and NKp30. As shown in Fig. 3.10, treatment of NK cells with VPA and 
SAHA clearly reduced the ability of anti-NKp46 and anti-NKp30 mAbs to induce NK cell-
mediated lysis.  
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Figure 3.10: HDACi suppress NK cell function. A 4 h NK cell cytotoxicity was assessed in a redirected killing 
assay against the FcγR
+ P815 target cell line either in the presence or absence of mAbs to the indicated receptors. 
Columns represent means of triplicate of one representative experiment; error bars indicate ± SD. 
 
These findings suggest that HDACi may affect NK cell function by interfering with the 
expression and the function of NKp46 and NKp30 triggering receptors.  
 
3.9 HDACi impair granule exocytosis and inhibit IFN-γ production  
To validate the effect of HDACi on NKp46 and NKp30 expression and function, perforin and 
granzyme B degranulation after cross-linking of NKp46 and NKp30 with mAbs was 
analyzed. As shown in Fig. 3.11a, an impaired granzyme B release was observed upon 
treatment of NK cells with VPA and SAHA. Cross-linking of NK cells with mAbs resulted in 
increased granzyme B release, further indicating the direct effect of HDACi on NKp46 and 
NKp30. Similar results were obtained for perforin degranulation (Fig. 3.11b). It is worthy to 
mention that intracellular perforin and granzyme B expressions using flow cytometry were 
not significantly affected by HDACi treatment (Fig. 3.11c). Furthermore, treatment of IL-2-
activated NK cells for 72 h with either VPA or SAHA also inhibited IFN-γ production (Fig. 
3.11d).  
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Figure 3.11: HDACi impair granule exocytosis and inhibit IFN-γ production. Cells were stimulated by cross-
linking the indicated NK receptors with appropriate mAbs. After overnight incubation at 37°C in IMDM + 10% 
FBS alone, supernatants were collected and analyzed in an ELISA assay specific for in vitro quantitative 
determination of [a] granzyme B and [b] perforin release. Columns indicate granzyme B or perforin granule 
release (pg/ml). [c] Flow cytometric analysis for intracellular granzyme B and perforin expression. [d] IL-2-
activated NK cells were treated for 72 h with or without VPA and SAHA, after which IFN-γ production was 
measured by ELISA. One representative of at least three separate experiments is shown; error bars indicate ± 
SD. 
 
3.10 SAHA and VPA suppress NFκB activation in IL-2-activated NK cells 
It was previously reported by Zhou et al [223] and Kim et al [224] that IL-2 increases NK cell 
cytotoxicity and proliferation through activation of NFκB signaling pathway. To verify a 
possible role of NFκB in this experiment, the effect of HDACi on NFκB binding was 
compared with that of a potent NFκB inhibitor BAY 11-7085. NK cells were cultured 
simultaneously for 4 days with 100 U/ml IL-2 and either HDACi or BAY 11-7085. NFκB 
activation was then measured. BAY 11-7085 as well as SAHA and VPA inhibited NFκB 
activity (Fig. 3.12a). BAY 11-7085 (not toxic to NK cells at concentration used- trypan blue 
exclusion counts) also abrogated NK cell lysis of K562 and suppressed surface expression of 
NK cell activating receptors NKp30, NKp44, NKp46 and inhibitory receptor NKG2A (Fig. 
d    
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3.12b). These results suggest that HDACi prevent IL-2-activated NK cell cytotoxicity by 
suppressing NK cell activating receptors in association with the inhibition of NFκB 
activation. 
 
 
 
0
50
100
150
200
250
300
350
400
NKp30
NKp44
NKp46
NKG2D
NKG2A
KIR
DNAM-1
r
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
Control
1µM BAY 11-7085
 
Figure 3.12: HDACi prevent NFκB activation. Primary NK cells from healthy donors were treated 
simultaneously with 100 U/ml IL-2 and either 0.5 mM VPA or 0.5 µM SAHA or 1 µM BAY 11-7085 for 4 days. 
Primary NK cells treated only with 100 U/ml IL-2 were used as control. [a] NFκB activation assay was 
performed as described in materials and methods. The relative luminescent values of IL-2 alone were set to 
100%, from which the percentage activation of other treated NK cells were deduced. [m] indicate mutated 
consensus oligonucleotide, [wt] indicate wild-type consensus oligonucleotide. Columns represent means of 
triplicate of one representative experiment; error bars indicate ± SD. [b] Flow cytometric analysis for the 
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expression of indicated NK cell activating or inhibitory receptors upon treatment with BAY 11-7085. Columns 
indicate relative expression of one representative of at least five separate experiments; error bars indicate ± SD. 
 
 
3.11 Viability of leukemic cells upon araC treatment 
MTT assay was performed to determine the viability of the leukemic cell lines used upon 
treatment with araC. Cytotoxic effects of araC, expressed as concetrations inhibiting 50% of 
cell growth (IC50) were decreased in araC-resistant cells when compared with parental cells. 
Resistance index (RI, ratio of IC50 in H9
r100
ARAC and H9 cells as well as in Molt-4
r100
ARAC 
and Molt-4 cells) of araC for H9 and Molt-4 cells were respectively 2.2 x 10
4 and 4.3 x 10
4 
(Table 3.2).   
 
Table 3.2: Cytotoxic effects of araC in Molt-4, Molt-4
r100
ARAC, H9 and H9
r100
ARAC cells 
________________________________________________________________________ 
C e l l   l i n e        I C 50 (µM)
a 
    __________________________________________________ 
Parental   Resistant   RI
b 
__________________________________________________________________________ 
 
Molt-4       0.029 ± 0.0018  1256 ± 234    4.3 x 10
4 
 
H9        0.034 ± 0.0047  756.8 ± 53.7    2.2 x 10
4 
__________________________________________________________________________ 
 
a Results represent mean values ± SD of three different experiments. 
b RI (Ratio IC50 resistant, IC50 parental cell 
lines). 
 
3.12 Cytotoxic activity of IL-2-activated NK cells against leukemic cell lines 
The cytolytic activity of IL-2-activated NK cells against parental and araC-resistant H9 and 
Molt-4 cell lines was determined. The results show that NK cells effectively kill parental H9 
and Molt-4 cell lines. Both araC-resistant cell lines showed higher sensitivity to NK cell lysis 
than parental cell lines (at E:T 4:1, 55% vs. 38% respectively for araC-resistant H9 and H9 
cells; 70% vs. 31% respectively for araC-resistant Molt-4 and Molt-4 cells; Fig. 3.13). The 
increased sensitivity of araC-resistant leukemic cells than parental cells was neither due to the    
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direct cytotoxic effect of araC on the cells nor the direct effects of araC on cell metabolism 
since araC-resistant cells used for the experiment were cultured for up to 10 subcultures 
without the drug. NK cell lysis of K562 cell line was used as positive control and it resulted in 
about 90% lysis at E:T 4:1.  
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Figure 3.13: NK cell cytotoxicity of parental and araC-resistant leukemic cells. Killing of H9 and Molt-4 cell 
lines and their araC-resistant counterparts was assessed by G3PDH release. Five thousand target cells were 
coincubated with IL-2-activated NK cells at the indicated E:T ratios for 4 h at 37°C. The results are mean ± SD 
of 3 independent experiments. 
 
3.13 Expression of NK cell activating and inhibitory ligands in leukemic cells 
The expression pattern of ligands for the NK cell activating/inhibitory receptor in both 
parental and araC-resistant cell lines was investigated to show whether it correlates with the 
lysis of leukemic cells by NK cells.  The observed increased lysis was associated with a 
corresponding increase in the cell surface expression of ULBP-2 and ULBP-3 in araC-
resistant H9 cells (relative expression: 380 vs. 217 for ULBP-2, 122 vs. 50 for ULBP-3) and 
Molt-4 cells (82 vs. 29 for ULBP-2, 31 vs. 6 for ULBP-3; Fig. 3.14a and b). There was no 
significant change in MHC-I expression level in both parental and araC-resistant H9 and 
Molt-4 cell lines. The mRNA expression of araC-resistant and parental cell lines used for this 
study was also evaluated using real time RT-PCR. As shown in Fig. 3.14c, an increased    
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ULBP-2 and ULBP-3 mRNA expression was observed in araC-resistant cell lines (1.57-fold 
ULBP-2, 5.93-fold ULBP-3 increase for araC-resistant H9 and 5.98-fold ULBP-2, 2.13-fold 
ULBP-3 for araC-resistant Molt-4) in comparison to their respective parental cell lines. This 
indicates that araC modifies NK cell activating receptor ligand expression at the 
transcriptional level. The effect of this modification appears to be maintained since several 
passaging of leukemic cell (at least 10 passages without araC treatment) continued to display 
this effect. 
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Figure 3.14: Expression of ligands for NK cell receptors in leukemic cells. [a] Flow cytometric analysis for the 
expression of ligands in [a] parental and araC-resistant H9 cells, and [b] parental and araC-resistant Molt-4 cells. 
Columns indicate relative expression of one representative of at least 3 separate experiments; error bars indicate 
± SD. [c] Real-time RT-PCR for the mRNA expression levels of ULBP-2 and ULBP-3 transcripts. Data are 
expressed as mRNA fold increase in araC-resistant H9 and Molt-4 cells relative to parental H9 and Molt-4 cells. 
Histograms are representative of three different experiments. Each experiment was run in duplicate; error bars 
indicate ± SD. 
 
3.14 NK cell recognition of leukemic cell lines via NKG2D 
In an attempt to understand a possible mechanism of the increased NK cell lysis of resistant 
leukemic cells as well as the functionality of NKG2D ligands, mAb masking experiments 
were performed. For this purpose, parental as well as araC-resistant H9 cell lines were 
selected for a 4 h cytotoxicity assay, since they displayed increased sensitivity to NK cell-
mediated cytotoxicity as well as increased NKG2D ligand densities on their cell surfaces 
(80% increase in ULBP-2 surface expression in all araC-resistant cell lines used). As shown 
in Fig. 3.15, blocking PVR on parental and araC-resistant H9 cells did not show significant 
decrease in NK cell lysis (36% vs. 33%, 58% vs. 50% respectively for H9 and araC-resistant 
H9 cells). However blocking ULBP-2 or ULBP-3 alone showed a strong inhibition of NK cell 
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lysis (36% vs. 3% ULBP-2 and 4% ULBP-3, 58% vs. 4% ULBP-2 and 15% ULBP-3 
respectively for H9 and araC-resistant H9 cells). It is worthy of note that in parental H9 cell 
line, the expression level of ULBP-2 and ULBP-3 was 8-fold and 1.9-fold respectively higher 
than that of PVR, while in araC-resistant H9 cell line the expression level of ULBP-2 and 
ULBP-3 was approximately 8.8 and 2.8-fold respectively higher than that of PVR. Combined 
blocking of ULBP-2 and ULBP-3 on araC-resistant H9 cells resulted in total abrogation of 
NK cell lysis. A 100% inhibition of NK cell lysis was also observed upon blocking NKG2D 
on NK cells (Fig. 3.15). The results suggest that NK cell activation via NKG2D receptor-
ligand binding is the possible mechanism involved in the increased lysis of araC-resistant H9 
cell line. 
 
 
 
 
 
 
 
Figure 3.15: NK cells recognize leukemic cells via NKG2D receptor. Five thousand H9 and araC-resistant H9 
cells were coincubated with IL-2-activated NK cells at E:T ratio 4:1 for 4 h at 37°C either in  the absence or 
presence of 10 µg/ml mAb. IgG isotype control was used as negative control. The results are mean ± SD of 3 
independent experiments.   
 
3.15 Possible mechanism of increased ligand expression in araC-resistant leukemic cells  
ERK and AKT may influence sensitivity of leukemic cells to araC [225-227]. Moreover, both 
ERK and AKT were shown to be involved in the regulation of expression of NKG2D ligands 
[199, 228]. For these reasons, both ERK and AKT signaling pathways were studied for their 
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constitutive activation status in both parental and araC-resistant cells. Western blot analyses 
using parental H9 as well as araC-resistant H9 cells showed a stronger constitutive 
phosphorylated ERK but not AKT in araC-resistant H9 cells. Constitutive activation of ERK1 
(p44) was particularly diminished in parental H9 cells (Fig. 3.16a). The enhanced constitutive 
phosphorylated ERK in araC-resistant H9 cells was confirmed by FACS analysis (relative 
expression: 229 ± 12 vs. 186 ± 14 for araC-resistant H9 and parental H9 cells respectively; 
Fig 3.16b).  
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Figure 3.16: Mechanism of increased ligand expression in araC-resistant cells. [a] The same amount of cell 
extracts prepared from the same passage of H9 and araC-resistant H9 cell cultures was used for western blot 
analyses. Constitutive AKT and ERK activation was assessed using antibodies that recognize AKT 
phosphorylated at ser-473 and ERK1/2 phosphorylated at Thr202/Tyr204. [b] Flow cytometric analysis for 
b 
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constitutive phosphorylated ERK expression. Data are representative of at least three experiments, error bars 
indicate ± SD. 
 
3.16 Role of ERK signaling in NKG2D ligand expression 
To verify the role of ERK signaling pathway in NKG2D ligand expression, FACS analysis 
and cytotoxicity assay were performed upon ERK inhibition of parental and araC-resistant H9 
cells using 20 µM of the ERK activation inhibitor PD98059. Treatment of parental H9 and 
araC-resistant H9 cells with PD98059 impaired NK cell lysis (from 50% to 39% and 68% to 
43% for H9 and araC-resistant H9 respectively; Fig. 3.17a) and decreased ULBP-2 (relative 
expression from 182 to 152 and 266 to 102 for H9 and araC-resistant H9 respectively) and 
ULBP-3 (relative expression from 24 to 14 and 60 to 49 for H9 and araC-resistant H9 
respectively) expression (Fig. 3.17b). Taken together, these results demonstrate that increased 
sensitivity of araC-resistant leukemic cells to NK cell lysis is due to higher NKG2D ligand 
expression, resulting from more active ERK but not AKT signaling pathway.  
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Figure 3.17: ERK signaling in NKG2D ligand expression. Parental and resistant cells were treated for 48 h with 
the ERK activation inhibitor PD98059. [a] IL-2-activated NK cell cytotoxicty and [b] flow cytometric analysis 
for ULBP-2 and ULBP-3 expression were determined. Results are representative of 3 different experimens. 
Error bars indicate ± SD.
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4.0 Discussion 
4.1 Luminescent assay 
Properly designed coupled luminescent assays are able to combine the advantages of specific 
assays for enzyme function with the very great sensitivity of luminescent detection methods. 
In coupled luminescent assays, the inherent sensitivity of luciferase detection is enhanced by 
the amplification effect of enzyme turnover, which produces thousands, millions, or billions 
of high-energy molecules for each molecule of enzyme. The luminescent signal is produced 
by firefly luciferase acting on adenosine triphosphate (ATP), which in turn is produced by the 
coupled reactions of G3PDH and phosphoglycerokinase (PGK), two consecutive enzymes of 
the glycolytic pathway. G3PDH, a very abundant enzyme in all known cells, is measured to 
quantify release (and therefore cell death and/or membrane damage). The fact that G3PDH is 
a natural component of cells, and does not need to be introduced into the cells in any manner, 
distinguishes this assay from all methods which require prelabeling of the cells, or 
transfection, transformation, or other methods of introducing proteins or other molecules into 
the target cells in order to generate a signal in a later step [196].  
 
The G3PDH /PGK/luciferase (GPL) coupled luminescent assay introduced by Corey et al 
[196] addressed several problems of the methods mentioned above. Nevertheless, the GPL 
assay is cumbersome to execute in that it involves four transfer steps (cocktail to reaction 
vessel, sample to reaction vessel, luciferase to luminance vessel, aliquot of reaction to 
luciferase) and two incubations prior to actual read. Moreover, since the assay is not 
compatible with live cells, live cells need to be separated from the supernatant by 
centrifugation prior to the assay.  
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4.2 Establishing CLM to measure NK cell cytotoxicity 
CLM enjoys the features of GPL assay. In contrast to the GPL assay, CLM is a one-step 
homogeneous system in which the sample being tested is mixed with the reagent cocktail and 
neither separation of live cells from supernatant nor further transfers are required prior to 
readout.  
 
CLM was established by measuring the cytolytic activity of IL-2-activated NK cells against 
K562. To validate CLM, a NB model was used. Most NB cells are generally resistant to NK 
cell lysis [144] when compared to K562 that are readily lysed even with NK cells that have 
not been activated with lymphokine such as IL-2. All NB cell lines tested were resistant to 
non-activated NK lysis, but were readily lysed by IL-2-activated NK cells. This may be due at 
least in part to the failure of NB cells to express NKG2D ligands, as were observed for 
MICA/B in the present study. This is consistent with previous report which showed that 
NKG2D-activating receptor ligands on the surface of primary neuroblasts and NB cell lines 
are down-regulated [229, 230].  On the other hand, PVR was readily expressed by NB cells. 
PVR, a ligand recognized by DNAM-1 receptor [215, 217], was used in mAb blocking 
experiments to further validate CLM. DNAM-1 (CD226) which is expressed in virtually all 
human NK cells, T cells, monocytes, platelets and a subset of B-lymphocytes, is another 
surface molecule that has been shown to participate in the induction phase of NK cell 
activation. DNAM-1 is known to be involved not only in NK cell activation but also in cell-
cell adhesion [231-233].  This suggests that the adhesion of NK cells to NB cells could be 
mediated by DNAM-1-PVR interaction. The present results support previous observations 
[215] demonstrating that the assessment of PVR expression could be used as an 
immunological marker for the susceptibility of NB cells to NK cell-mediated attack.  
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Interestingly, the higher susceptibility of drug resistant NB cells to NK lysis than non-
resistant cells is shown in this report with CLM. UKF-NB-4, which possesses the intrinsic 
multidrug resistant (MDR) phenotype [234], and the drug-induced resistant UKF-NB-
2
rVCR
10 [202] cell line were more susceptible to NK cell-mediated lysis than the parental 
UKF-NB-2 and UKF-NB-3 cell lines. Also, araC-resistant leukemic cell lines were also more 
sensitive to NK cell lysis than their parental cell lines. This is of interest since induction of 
drug resistance in tumor cells as shown seems to be associated with changes in their 
sensitivity to NK cell-mediated lysis. Some studies demonstrated that multidrug resistant 
leukemic cells develop decreased sensitivity to NK cell-mediated lysis mainly at the level of 
killer/target recognition [235, 236]. On the other hand, multidrug resistant cells derived from 
some solid tumors may exert increased sensitivity to NK cell-mediated lysis by different 
mechanisms [237, 238]. The increased sensitivity of multidrug resistant NB cells and 
leukemic cells might suggest a role for drug resistance in NK cell-mediated cytotoxicity.    
 
CLM is a highly sensitive, safe and fast method to determine NK cell cytotoxicity. The 
features of CLM may be of particular importance in cases with small blood samples including 
pediatric patients with solid tumors or viral infections. 
 
4.3 SAHA and VPA suppress IL-2-mediated NK cell cytotoxicity  
Several reports have described the direct inhibition of NK cell function by several substances 
including cortisol, methylprednisolone, adiponectin, L-kynurenine, and All-trans retinoic acid 
(ATRA) [214, 220, 221, 224, 239, 240]. The glucocorticoid cortisol at concentrations up to 2 
µM was shown to repress the synthesis of both perforin mRNA and granzyme A in NK3.3 
cell line [239]. Cortisol also down-regulated LFA-1 and inhibited conjugate formation of 
NK3.3 cells with their target K562 cells, thereby completely abrogating cytotoxic function of 
NK3.3 cell line [239]. The corticosteroid methylprednisolone impaired the expression of    
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NKp30, NKp44 and NKp46 both in NK cells from patients undergoing allogenic bone 
marrow transplantation and in IL-2-activated NK cells from healthy individuals [220]. In the 
report by Chiossone et al [214] methylprednisolone was shown to inhibit NKp30 and NKp44 
surface expression in IL-2 and IL-15-cultured NK cells. Tyr phosphorylation of STAT1, 
STAT3 and STAT5 was also inhibited. Impairment of NK cell cytotoxicity was observed to 
strictly correlate with the inhibition of ERK1/2 phosphorylation and perforin release in IL-2 
and IL-15-cultured NK cells [214]. On the other hand, adiponectin suppressed IL-2-induced 
NK cell cytotoxicity by inhibiting NFκB signaling pathway and down-regulating IFN-γ, Fas 
Ligand (FasL) and TRAIL expression in NK cells [224]. The inhibition of surface expression 
of NKp46 and NKG2D as well as impairment of NK cell ability to kill target cells recognized 
via NKp46 and NKG2D was reported for the tryptophan catabolite L-kynurenine [221]. The 
cytotoxic activity of the NK cell line NK92 was also shown to be inhibited by ATRA. The 
researchers reported that ATRA suppressed NFκB activity and prevented the degradation of 
IκB, inhibited IFN-γ production and gene expression of granzyme B, NKp46 and NKp30 
[240]. Reports of the direct effect of HDACi on NK cell cytotoxicity however do not exist. 
 
The results shown in this study provide for the first time evidence that treatment of NK cells 
with HDACi can suppress their lytic activity against leukemic cells. NK cell inhibitory effects 
were associated with the suppression of surface expression and function of specific triggering 
receptors (NKp46 and NKp30) responsible for the induction of NK cell-mediated 
cytotoxicity. This inhibitory effect was also effective at the transcriptional level. Moreover, 
inhibition of IFN-γ production and impaired granule release were observed upon treatment of 
NK cells with VPA and SAHA. After cross-linking of NK cells with NKp46 and NKp30 
granzyme B and perforin granule release were increased, further indicating the direct effect of 
HDACi on NKp46 and NKp30. HDACi acted directly on selected NK cell receptors rather 
than by interfering with the ability of NK cells to respond to IL-2 since IL-2R expression    
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were not affected. On the other hand, surface expression levels of inhibitory receptors 
including KIR and NKG2A were not influenced by HDACi treatment, indicating a specific 
effect of HDACi on NK cell triggering receptors. 
 
4.4 HDACi-treated NK cells repress HDACi-induced enhanced NK cell sensitivity of 
leukemic cells   
Independent reports by Cinatl et al [144], Skov et al [146], and Armeanu et al [147] described 
an increased NK cell-mediated lysis of certain tumors upon treatment with VPA and SAHA. 
Although the present study found in concert with these reports [144, 146, 147] that treatment 
of leukemic cells with HDACi increases their sensitivity to NK cell lysis, the increased 
sensitivity was however reversed when NK cells were pretreated with SAHA. These findings 
suggest that direct inhibitory effect of HDACi on lytic NK cells may overweigh the HDACi-
induced increased sensitivity of leukemic cells to NK cell lysis. 
 
4.5 Mechanism of HDACi inhibition of NK cell cytolytic activity 
Optimal NK cell development and activation as well as cytolytic activity involve IL-2Rβ 
signals that also up-regulate expression of the pore-forming effector molecules 
perforin/granzyme [241-243]. The activation of NFκB by IL-2R signaling and its role in 
perforin regulation in NK cells was investigated by Zhou et al [223]. They demonstrated that 
IL-2-induced up-regulation of perforin in primary NK cells and in a model cell line (NK3.3) 
was blocked by two pharmacological inhibitors of NFκB activation. Direct evidence for the 
activation of the NFκB pathway by IL-2R signals in NK cells was shown to involve activation 
of IKKα kinase, IκB degradation, nuclear translocation of p50/65 complexes, and ultimately, 
transcriptional activation of the perforin gene via an NFκB binding element in its upstream 
enhancer [223]. Furthermore, NFκB proteins were shown to regulate the expression of genes 
involved in immune and inflammatory responses including IFN-γ and granzyme B [244, 245].    
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Blanchard and Chipoy [97] reviewed several reports demonstrating the inhibition of NFκB 
transcriptional activity after treatment with HDACi. Here, mechanisms of NFκB 
transcriptional inhibition by HDACi including inhibition of nuclear translocation and DNA 
binding of NFκB were illustrated [97]. Since HDACi did not modify IL-2R in this research, it 
is conceivable that HDACi might not interfere with IL-2 signaling in NK cells but rather 
directly modulate NFκB activity. In fact, some studies revealed that prevention of NFκB 
activity by pharmacological treatments [224] or a defective NFκB activation in patients with 
the genetic disorder hypohidrotic ectodermal dysplasia [246] leads to a deficient NK cell 
cytotoxicity. In concordance, the present findings strongly indicate that inhibition of NFκB 
activation by SAHA and VPA is an important molecular mechanism by which HDACi 
suppress NK cell cytotoxicity.  
 
4.6 AraC-induced resistance of leukemic cells increases their sensitivity to NK cell lysis  
Numerous experimental studies demonstrated that drug exposure may induce not only 
resistance but also change other properties of tumor cells which may be related to tumor 
growth, invasiveness and immunogenicity [203, 247, 248, 169, 210]. Acquired drug resistance 
of leukemic cells due to pretreatment with cytostatic drugs influences the sensitivity of 
leukemic cells towards cytotoxic lymphocytes [249-254]. While some reports show decreased 
sensitivity of drug-resistant leukemic cells to cellular cytotoxicity [235, 236, 252, 253], 
Posovszky et al [254] reported that chemotherapeutic drugs including araC sensitize pre-B 
acute lymphoblastic leukemia (ALL) cells for CD95- and cytotoxic T-lymphocyte- mediated 
apoptosis. The present study shows that resistance of T-leukemic cells to araC is associated 
with increased sensitivity to NK cell-mediated lysis. These effects were not due to direct 
activity of araC on cell metabolism but rather to selection of cell population with altered 
susceptibility to NK cells since the resistant cells cultured for up to ten passages (about fifty    
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days) in a medium without the drug were lysed by NK cells to a greater extent than the 
parental cell population. 
 
4.7 Mechanism of increased sensitivity of araC-resistant leukemic cells 
Recent studies have shown that NK cells display cytolytic activities by engagement of 
receptors involved in NK cell activation and inhibition [60]. Although NK cells can kill target 
cells spontaneously without prior stimulation, a delicate balance between signaling through 
inhibitory (KIR, CD94-NKG2A) and activating receptors (NCRs-NKp30, NKp44, NKp46, 
NKG2D and DNAM-1) tightly regulates their activation [60]. Moreover, the relevance of the 
NKG2D/NKG2D ligand system for the immune surveillance in patient leukemia cells has 
been described [255]. Salih and co-workers [255] reported that leukemia cells from patients 
variously express MICA/B and ULBP. They also showed that patient leukemia cells were 
lysed by NK cells in an NKG2D-dependent fashion. The proposed role of the NKG2D 
receptor in innate and adaptive immune responses to cellular and tissue stress is based on the 
ability of the receptor to stimulate cytotoxic effects of NK cells and T cells against virally 
infected cells and tumor cells in vitro and in vivo [1]. Specifically, NKG2D receptor 
activation can induce target cell lysis and trigger the production of cytokines [42, 256] and 
chemokines [42, 257, 258], as well as perforin and granzyme involved in cellular lysis [259]. 
Based on these reports the role of specific ligands for NK cell activating receptors in the 
susceptibility of parental and araC-resistant leukemic cells to NK cell lysis was investigated. 
H9 and Molt-4 cells express some NKG2D ligands (particularly ULBP-2 and ULBP-3) in 
addition to PVR while they do not express other NKG2D ligands including MICA and MICB. 
This is in concordance with the hypothesis by Pende and coworkers [260] stating that most T-
cell leukemia cell lines are characterized by a MICA
-ULBP
+ phenotype. The results in this 
study, with particular reference to the blocking experiments, show that increased expression 
of ULBP-2 and ULBP-3 rendered araC-resistant leukemic cell lines to become more sensitive    
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to NK cell lysis. Blocking PVR with mAb could not inhibit NK cell lysis, suggesting that 
DNAM-1 is not involved in NK cell lysis of H9 and Molt-4 cell lines. The increased NK cell 
lysis of araC-resistant leukemic cells was observed despite expression of MHC-I molecules 
on their surface. These findings suggest that ULBP-NKG2D interaction is a major 
determinant for susceptibility of H9 and Molt-4 cell lines to NK cell lysis. Recent experiments 
demonstrated that NKG2D/NKG2D ligand system stimulates immune surveillance of tumors 
[48, 261, 262]. The capacity of the NKG2D ligand-expressing tumor cell lines to stimulate 
tumor immunity in vivo was critically dependent on the expression levels of NKG2D ligands 
on the tumor cell surface. In another study NKG2D ligand surface expression led to increased 
susceptibility of malignant or virus-infected cells to NK cell-or T cell-mediated lysis [42, 
256]. Since NK cell activity is guided by a balance of activating and inhibitory signals, and an 
enhanced NKG2D ligand expression is able to trigger NK cells overcoming inhibitory signals 
by MHC-I molecules [38, 42], even modest changes in NKG2D ligand expression may 
critically influence NK cell cytotoxic potential. 
 
4.8 Mechanism of increased expression of NKG2D ligands in araC-resistant leukemic 
cells 
Cell regulatory pathways such as ERK or AKT may influence the sensitivity of leukemic cells 
to araC [225-227]. Treatment of leukemic cells with inhibitors of AKT or ERK pathways was 
shown to increase their sensitivity to araC treatment [225-227]. Experiments performed in this 
study show both AKT and ERK to be constitutively activated in H9 cells, with increased 
activation of ERK1 (p44) but not AKT in resistant cells relative to their parental counterparts. 
Treatment of H9 cells with pharmacological inhibitors of ERK or AKT showed no toxicity to 
the cells and did not significantly influence activity of araC in resistant cells.  
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Gasser and co-workers [263] showed an induction of NKG2D ligand up-regulation by DNA 
damaging conditions such as ultraviolet light and the chemotherapy agents- cisplatin and 
araC- in fibroblasts and transformed ovarian epithelial cells from mice. NKG2D ligand 
expression was induced at the transcriptional level by mechanisms involving ataxia-
telangiectasia-mutated (ATM) and ATM-and Rad-3-related (ATR) protein kinases [263]. 
Both AKT and ERK were also shown to increase the expression of NKG2D ligands and the 
sensitivity to NK cell-mediated lysis of transformed cells derived from solid tumors and 
leukemia [199, 228]. In fact, while Borchers et al [199] reported the involvement of ERK 
signaling in the induction of surface expression of NKG2D ligands in human tumor cells 
following H2O2-induced oxidative stress, Boissel et al [228] demonstrated that NKG2D ligand 
expression in chronic myeloid cells is regulated posttranscriptionally by BCR/ABL kinase 
through activation of PI3K and mammalian target of rapamycin (mTOR). The results 
presented in this study demonstrate that ERK but not AKT activation is associated with 
increased ULBP-2 and ULBP-3 expression resulting in enhanced sensitivity of araC-resistant 
leukemic cells to NK cell lysis.   
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5.0 Conclusion 
In the course of this research, a highly sensitive coupled luminescent method (CLM) based on 
glyceraldehyde-3-phosphate dehydrogenase (G3PDH) release from injured target cells for the 
measurement of NK cell cytotoxicity was first established. In contrast to common methods 
like 
51Cr or Eu
3+ release, CLM does not require the pre-treatment of target cells with labeling 
substances which could be toxic or radioactive. CLM provides a highly sensitive, safe, 
material saving (low E:T ratio is needed) and fast procedure for measurement of NK cell 
activity. CLM was then used to investigate the effect of HDACi including SAHA and VPA on 
the cytolytic activity of IL-2-activated NK cells and on the sensitivity of parental and araC-
resistant leukemic cells to NK cell lysis.  
 
SAHA and VPA at therapeutic relevant concentrations inhibited the cytotoxicity of NK cells 
against human leukemic cells. This inhibition was associated with decreased surface 
expression and function of NK cell activating receptors NKp30 and NKp46 as well as 
impaired granule exocytosis and inhibition of IFN-γ production. NFκB activation in IL-2-
activated NK cells was inhibited by both HDACi.  Pharmacologic inhibition of NFκB activity 
resulted in similar effects on NK cell activity like those observed for HDACi. These results 
demonstrate for the first time that HDACi prevent NK cytotoxicity by down-regulation of NK 
cell activating receptors probably through the inhibition of NFκB activation. VPA and other 
HDACi are being studied as potential treatment for leukemia and MDS and early reports 
suggest that they may have therapeutic effects in some forms of leukemia [87, 140, 141]. 
Moreover, vorinostat (SAHA) has recently been approved by the Food and Drug 
Administration for the treatment of CTCL [78]. On the other hand, VPA therapy was shown 
to be associated with the development of myelodysplastic changes in the marrow and acute    
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leukemia [264]. It has been proposed that VPA therapy may lead to secondary leukemia by 
increased DNA damage through chronic inhibition of HDAC [264]. It has also been 
demonstrated that in AML, NK cells express low levels of NCRs. The insufficiency of NCR-
ligand interactions has been hypothesized as the underlying cause of the low susceptibility of 
leukemic blasts to lysis by autologous NK cells [265]. It may be speculated that VPA-induced 
down-regulation of NCRs may lead to deficient immune control by NK cells and thus 
contribute to leukemogenesis associated with VPA therapy. It should be noted that SAHA 
which is a more potent inhibitor of HDAC than VPA [87] was also more potent inhibitor of 
IFN-γ production, granule release, NFκB activation, NCR expression, and NK cell lytic 
activity against leukemic cells. More studies are required especially with treated patients to 
further elucidate the multifaceted roles of HDACi on NK cell activity.  
 
Furthermore, it was demonstrated in this research, again for the first time, that T-cell leukemic 
cell lines that received araC treatment and became resistant to the drug are more sensitive to 
NK cell attack than their parental counterparts. This increased sensitivity was associated with 
a higher surface expression of ligands for the NK cell activating receptor NKG2D, notably 
ULBP-2 and ULBP-3 in araC-resistant H9 and Molt-4 cell lines. Blocking ULBP-2 and 
ULBP-3 or NKG2D with mAbs inhibited NK cell lysis. Constitutive activation of ERK but 
not AKT was higher in araC-resistant cell lines than in parental cell lines. Inhibition of ERK 
using ERK inhibitor PD98059 decreased both ULBP-2 and ULBP-3 expression and NK cell 
cytotoxicity. These results demonstrate that increased sensitivity of araC-resistant leukemic 
cells to NK cell lysis is due to higher NKG2D ligand expression, resulting from more active 
ERK signaling pathway.  
 
It is possible that part of the efficacy of some chemotherapies and radiotherapies, most of 
which activate the DNA damage response [266, 267], is due to the induction of NKG2D    
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ligands which consequently enhances sensitivity of the cell to the immune system. This favors 
the insertion of an early autologous NK cell immunotherapy following therapeutic 
chemotherapy in patients suffering from hematological malignancies. Furthermore, the data 
presented for araC-resistant leukemic cells suggest that development of resistance to 
chemotherapeutic drugs may be associated with increased immunogenicity of tumor cells. 
Since such changes persist after cessation of treatment, it is of interest to show whether 
emergence of chemotherapy-resistant tumor clones with increased sensitivity to NK cell lysis 
also appear in patients who become refractory to common treatments with araC or other 
chemotherapeutic agents. The pathway leading to the up-regulation of NKG2D ligands looks 
promising in the search of targets for design of therapeutic agents to enhance the 
immunogenicity of transformed cells while reducing overall toxicity.    
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5.0.1 Zusammenfassung  
Schnelle, empfindliche und material-sparende Methoden zur Messung der zytolytischen 
Aktivität natürlicher Killerzellen (NK), eine wichtige Determinante der NK Zell Funktion, 
sind entscheidend für die Analyse der physiologischen Funktion, als auch für die pathologisch 
veränderten Zustände des Immunsystems. Den Goldstandard für die Messung zellvermittelter 
Zytotoxizität stellt das Chromium (
51Cr) oder Europium (Eu
3+) release assay dar. Allerdings 
stellt die Messung der Zielzelllyse mittels dem 
51Cr oder Eu
3+ release assay eine 
zeitaufwendige Methode dar und die notwendige Markierung der Zielzellen mit radioaktiven 
Substanzen bedeutet eine drastische Manipulation. Darüber hinaus kommt es aufgrund der 
vielen Zellen, die für den Test benötigt werden, zu hohen Hintergrundwerten. Verschiedene 
andere Methoden zur Messung von Zell Zytotoxizität sind widersprüchlich und weisen 
zahlreiche Mängel auf. Im Verlauf dieser Forschungsarbeit wurde zur Messung der 
zytolytischen Aktivität von Interleukin (IL)-2-aktivierten NK Zellen gegen die NK Zell 
sensitive erythroleukämische Zelllinie K562 erstmals die hoch empfindliche gekoppelte 
Lumineszenz Methode (coupled luminescent method (CLM)) etabliert. Diese Methode basiert 
auf der Messung der Glyceraldehyd-3-phosphat-dehydrogenasefreisetzung (G3PDH) aus 
lysierten Zielzellen. Zur Validierung der CLM wurden NK-resistente Neuroblastom (NB) 
Zellen verwendet. Alle getesteten NB Zelllinien (UKF-NB-2, UKF-NB-3, UKF-NB-4 and 
UKF-NB-2
rVCR
10) wurden durch IL-2 aktivierte NK Zellen lysiert. Im Gegensatz zu 
herkömmlichen Methoden wie 
51Cr oder Eu
3+, ist es bei der CLM nicht nötig eine 
Vorbehandlung der Zielzellen mit radioaktiven oder toxischen Substanzen vorzunehmen. 
CLM stellt daher eine hochsensible, sichere und materialsparende Methode zur Messung von 
NK Zellen dar. 
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Zunächst wurde CLM eingesetzt, um den Effekt von Histon-Deacetylase Inhibitoren 
(HDACi), Suberoylanilid Hydroxam Säure (SAHA) und Valproin Säure auf die zytolytische 
Aktivität IL-2-stimulierter NK Zellen und die Empfindlichkeit parentaler und Cytarabin 
(araC)-resistenter leukämischer Zellen auf NK Zelllyse zu untersuchen.  
 
Die Verwendung von HDACi als Zytostatika zur Krebsbehandlung hat in letzter Zeit große 
Aufmerksamkeit errungen. Klinische Studien haben gezeigt, dass pharmakologisch relevante 
Mengen von HDACi wie SAHA oder VPA  den Patienten sicher verabreicht werden können, 
und dass somit eine Behandlung von Krebs möglich ist. Die antitumorale Aktivität von 
HDACi liegt dabei in der direkten Wirkung auf Tumorzellen, indem diese die Hemmung der 
unkontrollierten Zellteilung bewirken, sowie Apoptose induzieren. Außerdem können HDACi 
das Tumorwachstum durch Inhibierung der Angiogenese und Zunahme der Immunogenität 
der Tumorzellen beeinflussen. Jedoch wurde noch nichts über den direkten Effekt von 
HDACi  auf NK Zell Aktivierung beschrieben.   
 
Im Rahmen dieser Forschungsarbeit wurde festgestellt, dass SAHA und VPA in therapeutisch 
relevanten Konzentrationen die Zytotoxizität von NK Zellen gegen Tumorzellen inhibieren. 
Diese Inhibierung war sowohl assoziiert mit einer Abnahme der Oberflächenexpression und 
Funktion der NK Zell aktivierenden Rezeptoren NKp30 und NKp46 (natürliche zytotoxische 
Rezeptoren, NCR) als auch mit einer beeinträchtigten granulären Exozytose und Inhibierung 
der Interferon Gamma (IFN-γ) Produktion. Die Nuclear factor kappa B (NFκB) Aktivierung 
in IL-2-aktivierten NK Zellen wurde durch beide HDACi inhibiert.  Die pharmakologische 
Inhibierung der NFκB Aktivität zeigte ähnliche Effekte in der NK Zellaktivität wie mit 
HDACi. Diese Ergebnisse demonstrieren zum ersten Mal, dass HDACi über eine 
Herabregulierung von NK Zell aktivierenden Rezeptoren, vermutlich durch Inhibierung der 
NFĸB Aktivierung, die NK Zytotoxizität erniedrigen.     
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VPA und andere HDACi werden als Behandlungsmöglichkeiten für Leukämien und 
Myelodysplastische Syndrome in Betracht gezogen und neueste Untersuchungen zeigen erste 
therapeutische Effekte bei bestimmten Leukämieformen. Darüber hinaus wurde kürzlich 
Vorinostat (SAHA) zur Therapie des kutanen T-Zelllymphoms (CTCL) zugelassen. 
Andererseits wurden unter VPA-Therapie myelodysplastische Veränderungen im 
Knochenmark und akute Leukämien beobachtet. Es wird vermutet, dass eine VPA-Therapie 
durch zunehmenden DNA Schaden aufgrund einer chronischen Inhibierung durch HDAC, zu 
einer sekundären Leukämie führen kann. Weiterhin wurde bewiesen, dass bei akuter 
myeloischer Leukämie (AML) NK Zellen eine geringe Expression von NCR zeigen. Die 
Insuffizienz der NCR-Liganden Interaktionen wird als Ursache für die erniedrigte 
Empfindlichkeit der leukämischen Blasten gegenüber der autologen NK Zell induzierten Lyse 
angenommen. Es kann angenommen werden, dass die VPA induzierte Herabregulierung von 
NCR zu einer defizienten Immunkontrolle durch NK Zellen führt und so zur Entstehung von 
Leukämien durch die VPA Therapie beitragen könnte. Von Interesse ist weiterhin die 
Tatsache, dass SAHA, ein weit potenterer Inhibitor von HDAC ist als VPA. SAHA ist ein 
stärkerer Inhibitor der INF-γ Produktion, der granulären Freisetzung, der NFĸB Aktivierung, 
der NCR Expression und unterdrückt die lytische NK Zellaktivität gegen leukämische Zellen 
stärker. Es wird also erforderlich sein, besonders mit behandelten Patienten weitere Studien 
durchzuführen, um die vielfältigen Einflüsse der HDACi auf die NK Zellaktivität zu 
verstehen.  
 
Zahlreiche experimentelle Studien haben belegt, dass die Medikamentengaben nicht nur 
Resistenzen induzieren, sondern auch andere Eigenschaften der Tumorzellen im Bezug auf 
Wachstum, invasives Verhalten und die Immunogenität verändern. Erworbene Resistenzen 
gegen Medikamente bei leukämischen Zellen, aufgrund einer Vorbehandlung mit Zytostatika, 
beeinflussen die Sensitivität der leukämischen Zellen  gegenüber der zytotoxischen Aktivität    
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der NK Zellen. Während einige Veröffentlichungen eine Abnahme der Sensitivität von 
chemoresistenten Leukämie Zellen gegenüber der zellulären Zytotoxizität vorweisen,   
konnten Posovszky et al. (1999) zeigen, dass Chemotherapeutika wie araC, pre-B akute 
lymphoblastische Leukämie (ALL) - Zellen für CD95 - und zytotoxische  T Lymphozyten 
vermittelte Apoptose sensibilisieren. Neuere Studien konnten zeigen, dass NK Zellen durch 
die Bindung von Rezeptoren zytolytische Aktivität entfalten, die in NK Zellaktivierung und 
Inhibierung involviert sind.  NK Zellen sind in der Lage Zielzellen spontan und ohne 
vorausgegangenen Stimulus abzutöten. Darüber hinaus ist eine Aktivierung der NK Zellen 
über eine empfindliche Balance zwischen den transduzierten Signalen durch inhibitorische 
Rezeptoren (KIR, CD94-NKG2A) und aktivierende Rezeptoren (NCRs - NKp30, NKp44, 
NKp46, NKG2D und DNAM-1) reguliert. Zudem wurde die Bedeutung des NKG2D/NKG2D 
Liganden Systems als Überwachungsmarker für die Immunität von leukämischen Zellen 
beschrieben. Salih et al. (2003) berichteten, dass Leukämiezellen von Patienten 
verschiedenartiger Haupthistokompatibilitätskomplexe der Klasse I (MHC-I) verwandte A/B-
Ketten (MICA/B) und UL16 Binding Protein (ULBP) exprimieren. Sie zeigten außerdem eine 
NKG2D abhängige NK-induzierte Zelllyse leukämischer Zellen. 
 
In dieser Forschungsarbeit wurde wiederum erstmals gezeigt, das T Zell Leukämie Zelllinien, 
die zuvor mit araC behandelt wurden und eine Chemoresistenz erlangten, weitaus sensibler 
gegenüber den NK Zellen - Attacken waren, als parentale, unbehandelte Zellen. Diese Effekte 
sind nicht direkt der Wirkung von araC auf den Zellmetabolismus zuzuschreiben, sondern 
eher einer Selektion der Zellen, deren Empfänglichkeit für NK Zellen verändert ist. Die 
resistenten Zellkulturen, die bis zu zehn mal in medikamentenfreien Medium passagiert 
wurden, konnten durch die NK Zellen in einem größeren Ausmaß lysiert werden, als die 
parentale Zellpopulation.     
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Die erhöhte Sensitivität war assoziiert mit einer gesteigerten Oberflächenexpression der 
Liganden für die NK Zell aktivierenden Rezeptoren NKG2D, besonders ULBP-2 und ULBP-
3  in araC-resistenten H9 und Molt-4 Zelllinien. Die Blockade von ULBP-2 und ULBP-3 oder 
NKG2D  durch monoklonale Antikörper  inhibierte die NK Zell-vermittelte Lyse. Die 
konstitutive Aktivierung der extrazellulären Signal-regulierten Kinase (ERK), aber nicht 
AKT, war höher in araC-resistenten Zelllinien als in parentalen Zelllinien. Eine Inhibierung 
von ERK durch den ERK Inhibitor PD98059 führte zu einer Abnahme der Expression von 
ULBP-2 und ULBP-3 und der NK Zell Zytotoxizität. Diese Ergebnisse deuten darauf hin, 
dass eine erhöhte Sensitivität von araC-resistenten leukämischen Zellen gegenüber einer NK 
Zell-vermittelten Lyse darauf zurückzuführen ist, dass die durch einen aktivierten ERK 
Signaltransduktionsweg ausgelöste Expression von NKG2D Liganden hochreguliert wird. 
 
Möglicherweise ist die Induktion der NKG2D Liganden, die die Empfindlichkeit  der Zellen 
gegenüber dem Immunsystem erhöht, Teil der Wirksamkeit von Chemo - und Radiotherapien. 
Dies favorisiert den Einsatz einer frühen autologen NK Zellimmunotherapie, anschließend an 
eine therapeutische Chemotherapie bei Patienten die an einer hämatologischen 
Krebserkrankung leiden. Weiterhin zeigen die Daten für araC-resistente leukämische Zellen, 
dass eine Resistenzentwicklung von Krebszellen gegenüber Chemotherapeutika, mit einer 
erhöhten Immunogenität der malignen Zellen einhergehen kann. Da diese Veränderungen 
nach Beendigung der Behandlung bestehen bleiben, ist es von Interesse aufzuzeigen, ob das 
Auftreten von chemotherapieresistenten Tumor Klonen mit erhöhter Sensitivität für NK Zell-
vermittelte Lyse ebenfalls bei Patienten auftritt, die unempfindlich gegenüber bekannten 
Therapien mit araC oder anderen Chemotherapeutika geworden sind. Der Pathway, der zu 
einer Hochregulierung der NKG2D Liganden führt, ist viel versprechend für die Suche nach 
Zielen für das Design von therapeutischen Mitteln, um die Immunogenität von 
transformierten Zellen zu verstärken und die  Toxizität zu reduzieren.         
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Abbreviations 
ADC  Analog to digital converters 
ADCC  Antibody-dependent cellular cytotoxicity 
ADP Adenosine  diphosphate 
AML  Acute myeloid leukemia 
APC Allophycocyanin 
APS Ammoniumpersulphate 
AraC  Cytosine arabinoside, cytarabine, 1-β-D-arabinofuranosylcytosine 
AraCDP araC  diphosphate 
AraCMP araC  monophosphate 
AraCTP araC  triphosphate 
ATCC  American type culture collection 
ATM Ataxia-telangiectasia-mutated 
ATP Adenosine  triphosphate 
ATR  ATM-and  Rad-3-related 
ATRA  All-trans retinoic acid 
BCL-6  B cell lymphoma-6 
BMT Bone  marrow  transplantation 
BSA  Bovine serum albumin 
cAMP  Cyclic adenosine monophosphate 
CD  Cluster of differentiation 
cDNA Complementary  DNA 
CML Chronic  myeloid  leukemia 
CO2  Carbondioxide 
51Cr Chromium 
Ct Cycle-threshold 
CTCL  Cutaneous T cell lymphoma 
dCK Deoxycytidine  kinase 
DC Dendritic  cells 
DCSign DC-specific  intercellular  molecule 3-grabbing nonintegrin 
DEPC Diethylpyrocarbonate 
DMF Dimethylformamide 
DMSO Dimethylsulfoxide 
DNA Deoxyribonucleic  acid 
DNAM-1  DNAX accesorry molecule-1 
DPG Diphosphoglycerate 
DSMZ  Deutsche Sammlung von Mikroorganismen und Zellkulturen 
dUTP Deoxyuridine  triphosphate 
ECL   Enhanced chemiluminescence 
EDTA Ethylenediaminetetraacetic  acid 
ELISA  Enzyme linked immunosorbent assay 
eNOS  Endothelial nitric-oxide synthase 
ERK  Extracellular signal-regulated kinase 
Eu
3+  Europium 
FACS  Fluorescent activated cell sorter 
FBS  Fetal bovine serum 
FITC Fluorescein  isothiocyanate 
FSC  Forward angle light scatter 
g Gram    
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g  Relative centrifugal  force (RCF) 
G3P Glyceraldehyde-3-phosphate 
G3PDH Glyceraldehyde-3-phosphate dehydrogenase 
GPI Glycosylphosphatidylinositol 
GPL G3PDH/Phosphoglycerokinase/luciferase 
GVL  Graft versus leukemia 
h Hour 
H2O Water 
H2O2 Hydrogen  peroxide 
HAT Histone  acetyltransferase 
HCl Hydrochloric  acid 
HDAC Histone  deacetylase 
HDACi  Histone deacetylase inhibitors 
hENT1  Human equilibrative nucleoside transporter 
HIF1  Hypoxia inducible factor 1 
HLA  Human leucocyte antigen 
IC Inhibitory  concentration 
ICAM-1 Intercellular  cell  adhesion  molecule-1 
IFN Interferon 
IgG Immunoglobulin 
IL-2 Interleukin-2 
IMDM  Iscove’s modified dulbecco’s medium 
IRF  IFN regulatory factor 
ITAM  Immunoreceptor tyrosine-based activating motif 
ITIM  Immunoreceptor tyrosine-based inhibitory motif 
kD Kilo  dalton 
KIR  Killer inhibitory receptor 
LDH Lactate  dehydrogenase 
LFA-1  Leucocyte function antigen-1 
LPS   Lipopolysaccharide 
M Molar 
mAb Monoclonal  antibody 
MACS  Magnetic associated cell sorting 
MAPK   Mitogen activated protein kinase 
MDR Multidrug  resistant 
MDS Myelodysplastic  syndrome 
MgCl2 Magnesium  chloride 
MHC  Major histocompatibility complex 
MICA  MHC class I chain-related molecule A 
MICB  MHC class I chain-related molecule B 
Min   Minute 
ml Milliliter 
mM Millimolar 
mRNA Messenger  RNA 
mTOR  Mammalian target of rapamycin 
NaCl Sodium  chloride 
NAD
+  Nicotinamide adenine dinucleotide oxidized form 
NADH  Nicotinamide adenine dinucleotide reduced form 
NaHCO3  Sodium hydrogen carbonate    
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NB Neuroblastoma 
NCAM  Neural cell adhesion molecule 
NCR Natural  cytotoxicity  receptor 
NFκB  Nuclear factor kappa B 
NK Natural  killer 
NKG2A  Natural killer group 2A 
NKG2D  Natural killer group 2D 
NKp  Natural killer protein 
nm Nanometer 
NO Nitric  oxide 
NP-40 Nonidet  40 
NT Nucleoside  transporter 
PAGE Polyacrylamide  gel  electrophoresis 
PBMC  Polyclonal blood mononuclear cell 
PBS  Phosphate buffered saline 
PCR  Polymerase chain reaction 
PE Phycoerythrin 
PG Phosphoglycerate  kinase 
PI Propidium  iodide 
PI3K Phosphatidylinositol-3-kinase 
PIM Protease  inhibitor  mix 
PMT  Photo multiplier tube 
PVR  Polio virus receptor 
RNA Ribonucleic  acid 
ROS  Reactive oxygen species 
RT-PCR Reverse  transcriptase  polymerase chain reaction  
SAHA  Suberoylanilide hydroxamic acid 
SAP Signaling  lymphocyte  activation molecule-associated protein 
SB Sodium  butyrate 
SD Standard  deviation 
SDS  Sodium dodecyl sulphate 
SSC Sideward  scatter 
STAT  Signal transducers and activator of transcription 
TAP  Transporter associated with antigen processing 
TBP2  Thioredoxin protein 2 
TEMED N,N,N’,N’-Tetramethylethylenediamine 
TNF  Tumor necrosis factor 
TRAIL  Tumor necrosis factor related apoptosis inducing ligand 
TSA Trichostatin  A 
TUNEL  Terminal deoxynucleotidyl transferase dUTP nick-end labeling 
U Unit 
ULBP  UL16 binding protein 
VCR Vincristine 
VEGF Vascular  endothelial growth factor 
VPA Valproic  acid 
vs Versus 
XLP X-linked  lymphoproliferative   
°C Degree  celcius 
µg Microgram    
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µl   Microliter 
µm Micrometer 
µM Micromolar   
% Percent 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
   Appendix 
  142
Curriculum Vitae 
 
Surname: Ogbomo 
 
First Name: Henry 
 
Date of Birth: 18
th January 1975 
 
Place of Birth: Benin City, Nigeria 
 
Nationality: Germany 
 
Marital Status: Married with 2 children 
 
Contact Address: Am Ruhestein 20, 60529 Frankfurt, Germany 
 
Email: excelrector@yahoo.com 
 
Telephone: +49-176-28708338 
 
Educational Background 
I n s t i t u t i o n s   a t t e n d e d        D a t e  
Johann Wolfgang Goethe-University, Frankfurt,  Germany    Oct  2000-Feb  2004 
Deutsch in Deutschland, Frankfurt,  Germany     Jul  2000-Oct  2000 
Volkshochschule,  Hanau,  Germany       Nov  1999-Jun  2000 
University of Benin, Benin City, Nigeria          Oct 1991-Dec 1996    
   Appendix 
  143
Edokpolo Grammar School, Benin City,  Nigeria     Oct  1986-Sep  1991 
Ebenezer Primary School, Benin City, Nigeria        Sep 1981-Jul 1986 
 
Certificates  obtained       Date 
Diploma  in  Biology         Feb  2004 
German  language  certificate  (DSH)       Mar  2001 
Bachelor  of  Science  (B.Sc.)  Microbiology      Dec  1996 
Senior  School  Certificate        Sep  1991 
 
Working Experience 
Feb 2005 to date: Research assistant/Ph.D student at the laboratory of Prof. Dr. Jindrich 
Cinatl Jr., Hospital of Johann Wolfgang Goethe University, Frankfurt/Main, Germany with 
the aim of obtaining a doctorate degree in pharmaceutical technology. Topic: “Establishment 
and application of a highly sensitive coupled luminescent method (CLM) to study natural 
killer cell cytolytic activity”. 
  
June 2003 – Feb 2004: Diploma thesis (Topic: “Modulation of PSA-NCAM expression on 
neuroblastoma cells by valproate”) at the urology research laboratory of Prof. Dr. Roman 
Blaheta, Clinic for Urology and Pediatric Urology, Hospital of Johann Wolfgang Goethe 
University, Frankfurt, Germany. Here I mastered several cell culture techniques, flow    
   Appendix 
  144
cytometry, as well as molecular biology working methods. 
 
May 1998 – October 1998: Laboratory scientist at the pharmaceutical company SCIO 
Nigeria Ltd, Benin City, Nigeria. 
 
June 1997 - April 1998: National Youth Service Corps (NYSC) at National Oil and 
Chemical Marketing Plc., Lagos, Nigeria. I was involved in the sales and marketing of 
chemical products like bitumen.  
 
April 1993 – July 1993: Industrial attachment at the medical laboratory of Nigerian National 
Petroleum Corporation staff clinic, Benin City, Nigeria. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
   Appendix 
  145
Publications 
•  Kleinschmidt MC, Michaelis M, Ogbomo H, Doerr HW, Cinatl J Jr. Inhibition of 
apoptosis prevents West Nile virus induced cell death. BMC Microbiol. 2007; 7:49. 
 
•  Ogbomo H, Michaelis M, Kreuter J, Doerr HW, Cinatl J Jr. Histone deacetylase 
inhibitors suppress natural killer cell cytolytic activity. FEBS Lett. 2007; 581(7):1317-
22.  
 
•  Ogbomo H, Hahn A, Geiler J, Michaelis M, Doerr HW, Cinatl J Jr. NK sensitivity of 
neuroblastoma cells determined by a highly sensitive coupled luminescent method. 
Biochem Biophys Res Commun. 2006; 339(1):375-9. 
 
•  Beecken WD, Engl T, Ogbomo H, Relja B, Cinatl J, Bereiter-Hahn J, Oppermann E, 
Jonas D, Blaheta RA. Valproic acid modulates NCAM polysialylation and 
polysialyltransferase mRNA expression in human tumor cells. Int Immunopharmacol. 
2005; 5(4):757-69. 
 
•  Blaheta RA, Bogossian H, Beecken WD, Jonas D, Hasenberg C, Makarevic J, 
Ogbomo H, Bechstein WO, Oppermann E, Leckel K, Cinatl J Jr. Mycophenolate 
mofetil increases adhesion capacity of tumor cells in vitro. Transplantation 2003; 
76(12):1735-41. 
 
 
 
    
   Appendix 
  146
Acknowledgement 
I want to first of all thank the Almighty God for His grace and for giving me life and strength 
to carry out this work. 
 
My thanks go also to my parents, brother and sisters for their encouragement and moral 
support during the course of my work. 
 
Many more thanks go to Prof. Dr. Jindrich Cinatl Jr for personally supervising my work and 
for making his laboratory available to me. His excellent supervision brought out the best in 
me. He was not just a supervisor but also a mentor to me.  
 
I thank PD Dr. Martin Michaelis for actively engaging in searching for funds for my research. 
In fact, part of funds for my research was from the European Commission-funded Co-
operative Research (COOP-CT-2004, Contract Nr. 512864) and Specific Targeted Research 
Projects (LSHB-CT-2004, Contract Nr. 512054)- sourced by Prof. Dr. Jindrich Cinatl Jr and 
PD Dr. Martin Michaelis. The other part of funding came from the friendly society "Hilfe für 
krebskranke Kinder Frankfurt e.V." and the "Frankfurter Stiftung für krebskranke Kinder". I 
thank all sponsors. 
 
I also wish to thank the director of the Institute for Medical Virology, Prof. Dr. Hans Wilhelm 
Doerr for his motivation and for allowing me to carry out my work at his institute. He always 
personally came to congratulate me whenever my work was accepted for publication.  
 
I also want to thank Prof. Dr. Jörg Kreuter for accepting to supervise my doctoral thesis for 
the faculty of chemisty and pharmaceutical sciences.    
   Appendix 
  147
My thanks also go to all staff at the Institute for Medical Virology, Hospital of J.W. Goethe-
University, Frankfurt/Main. I thank all Ph.D. students and technical assistants at the 
interdisciplinary laboratory for tumor and virus research for the good team work. I especially 
thank Rosy Schmidt and Elena Brandi-Barbarito for their technical assistance, Corinna 
Fleckenstein for her assistance in real time PCR. I also thank Karoline Bleymehl and Denise 
Klassert for their assistance in summarizing my dissertation in German. 
 
Above all, I specially thank my dear wife Sandrine and our lovely daughters Athalia and Eliya 
for always being there when I needed them the most. With their support I was able to fully 
concentrate on my work. Sandrine, my work became your priority and you never complained 
about the weekends I spent in the laboratory. You made sure all was well at home and with 
our daughters.  
 
 
 
 
 
 
 
 
 
 
 
 
    
   Appendix 
  148
Declaration 
I hereby declare that I independently performed and wrote this dissertation and used no 
literature or resource other than those indicated. 
 
 
 
 
 
 
Frankfurt am Main, January 2008          Henry Ogbomo 
 
 
 
 